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Tumor angiogenesis is necessary for cancer progression and requires active 
interaction between endothelial cells and tumor cells. It is well established that cancer 
cells secrete angiogenic factors to recruit and sustain tumor vascular networks. However, 
little is known about the effect of endothelial cell-secreted factors on the phenotype and 
behavior of tumor cells. The identification and characterization of signaling events 
initiated by tumor-associated endothelial cells may have important implications in cancer 
therapy. The hypothesis underlying this dissertation is that factors secreted by endothelial 
cells initiate signaling pathways in head and neck squamous cell carcinoma (HNSCC) 
cells that enhance tumor growth. 
 Here, we observed that soluble mediators from primary human dermal 
microvascular endothelial cells activate STAT3, Akt, and ERK signaling in HNSCC 
cells. HNSCC cells adjacent to blood vessels showed increased phosphorylation of 
STAT3, Akt, and ERK in xenograft human tumors. IL-6, CXCL8, and EGF are 
upregulated in endothelial cells co-cultured with HNSCC, and blockade of endothelial 
cell-derived IL-6, CXCL8, or EGF inhibited the activation of STAT3, Akt, or ERK in 
tumor cells, respectively. Notably, activation of these pathways by endothelial cells 
enhanced migration and inhibited anoikis of tumor cells. It is known that Bcl-2 is 
upregulated in tumor microvessels of patients with HNSCC. Here, we observed that Bcl-
x 
 
2 signaling induces expression of IL-6, CXCL8, and EGF, providing a mechanism for the 
upregulation of these cytokines in tumor-associated endothelial cells.  
We also observed that endothelial cell-induced Akt or ERK signaling in HNSCC 
has a compensatory effect whereas STAT3 pathway is activated independent of Akt or 
ERK. Among these three pathways, STAT3 presented the higher phosphorylation levels, 
and was mainly induced by endothelial cell-secreted IL-6. Interestingly, downregulation 
of IL-6 in tumor-associated endothelial cells inhibited tumor growth in xenograft human 
tumors. These results suggest that patients with HNSCC might benefit from targeted 
inhibition of signaling events initiated by tumor associated-endothelial cells. 
Collectively, this work expands the contribution of vascular endothelial cells to 
the pathobiology of cancer. It shows that endothelial cells function as the initiators of 






Squamous cell carcinoma (SCC) is the most common malignancy of the head and 
neck region. Head and neck squamous cell carcinoma (HNSCC) is a significant public 
health challenge and represents one of the sixth most common cancers in the world 
(Parkin et al., 2005). Despite many advances in prevention and treatment of other types 
of cancer, the five-year survival rate after diagnosis for HNSCC remains low, 
approximately 50%, which is considerably lower than that for most cancers (Jemal et al., 
2008). The limited survival of HNSCC patients is likely due to a high proportion of 
patients presenting with advanced disease stages, lack of suitable markers for early 
detection, and failure to respond to available chemotherapy (Forastiere et al., 2001; Mao 
et al., 2004). Their poor prognosis is also the reflection of the incomplete knowledge of 
the mechanisms underlying the malignant progression of this cancer type (Molinolo et al., 
2009). Therefore, the ability to gain insights into the complex molecular events leading to 
the development and progression of HNSCC will have important implications for the 





Head and neck squamous cell carcinoma 
 
Head and neck cancer includes malignant lesions arising in the oral cavity, larynx, 
and pharynx, with more than 500,000 new cases reported annually worldwide (Jemal et 
al., 2008; Parkin et al., 2005). Although most patients with stage I disease can be cured, 
around 10% relapse and die. For more advanced stages, the proportion of patients with 
relapses increases to 30% for stage II, 50% for stage III, and more than 70% for stage IV 
(Prince and Ailles, 2008). 
Several risk factors contribute to the development of HNSCC. Among them, 
carcinogen exposure, diet, oral hygiene, infectious agents, family history, and preexisting 
medical conditions all play a role, individually or in combination. Tobacco smoking is 
well established as the dominant risk factor for HNSCC, and this risk is correlated with 
the intensity and duration of smoking (Brennan et al., 1995; Ho et al., 2007; Zhang et al., 
2000). Heavy alcohol consumption is also an independent risk factor for HNSCC, 
particularly for cancers of the hypopharynx. Alcohol consumption, however, is most 
relevant for its ability to amplify the effects of tobacco smoke in a synergistic manner 
(Sturgis et al., 2004; Talamini et al., 2002). Although tobacco exposure and alcohol 
consumption are responsible for the vast majority of HNSCC that occur in the oral cavity, 
larynx, and hypopharynx, their role in promoting tumorigenesis of the oropharynx is less 
consequential. Instead, human papillomaviruses (HPV), and in particular HPV-16, has 
been established as a causative agent in up to 70% of oropharyngeal cancers (Gillison et 
al., 2000; Herrero et al., 2003; Hobbs et al., 2006; Mork et al., 2001; Wiest et al., 2002). 
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The progression of head and neck cancer, from a simple squamous hyperplasia 
through the advancing stages of squamous dysplasia to invasive squamous cell carcinoma 
is driven by the progressive accumulation of genetic alterations (Forastiere et al., 2001). 
Histologically, dysplasia refers to neoplastic alterations of the surface epithelium prior to 
invasion of the subepithelial connective tissues. These changes include abnormal cellular 
organization, increased mitotic activity, and nuclear enlargement with pleomorphism. 
These alterations are typically graded on a scale of 1 to 3 based on the severity of the 
atypia (mild, moderate, or severe dysplasia/carcinoma in situ). With progression, the 
carcinoma in situ breaks through the basement membrane and infiltrates the subepithelial 
connective tissue as cohesive nests and cords. With advanced tumor growth, nests of 
invasive tumor invade skeletal muscle, craniofacial bones, and facial skin. Invasion may 
be associated with tumor extension along nerves and involvement of lymphatic spaces 
(Pai and Westra, 2009). 
The initiation and progression of head and neck cancer is a complex multistep 
process that entails a progressive acquisition of genetic and epigenetic alterations 
(Califano et al., 1996b). An early model of head and neck tumorigenesis based on 
microsatellite analysis of allelic imbalances showed that the p53 gene is almost 
universally disrupted in HNSCC (Califano et al., 1996a; Poeta et al., 2007). In fact, 40% 
to 60% of patients with HNSCC present with a mutation of the p53 gene (Hollstein et al., 
1991; Somers et al., 1992). The loss of p53 function is associated with the progression 
from premalignancy to invasive disease (Forastiere et al., 2001) and increases the 
likelihood of further genetic progression (Boyle et al., 1993). Amplification of the 
oncogene cyclin D1, which constitutively activates cell cycle progression, is present in 
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30% to 50% of patients with HNSCC and is usually associated with invasive disease, 
early recurrence, and shortened survival (Callender et al., 1994; Sidransky, 1995). Loss 
of chromosomal region 9p21 is one of the most common genetic changes and occurs 
early in the progression of HNSCC (Cairns et al., 1995; van der Riet et al., 1994). The 
main effect of this loss is the inactivation of the CDKN2A (formerly p16) gene, an 
inhibitor of cyclin-dependent kinase (CDK) that is important in regulating the cell cycle 
(Kamb et al., 1994; Reed et al., 1996). This early inactivation is consistent with the 
findings that keratinocytes in culture often loose p16 function and thus escape senescence 
(Munro et al., 1999; Papadimitrakopoulou et al., 1997). More recently, epidermal growth 
factor receptor (EGFR) was found to be highly expressed in more than 95% of HNSCC. 
Notably, increased expression of the protein and its ligand is associated with poor 
prognosis (Kalyankrishna and Grandis, 2006). 
The model of the molecular progression of HNSCC demonstrates that tissue with 
a normal or benign appearance can also contain clonal genetic changes (Califano et al., 
1996b). Several studies suggest that early genetic changes do not necessarily correlate 
with observable changes in morphology (Rosin et al., 2000). Therefore, testing for these 
genetic alterations in early lesions may identify patients who are at the greatest risk for 
progression and lead to more definitive therapy (Forastiere et al., 2001). 
Field cancerization is the term used to describe the lateral spread of pre-malignant 
or malignant disease, often fatal, that develop in the head and neck, lungs, esophagus, or 
other regions of 10–40% of patients with HNSCC (Ha and Califano, 2003; Jones et al., 
1995). Field cancerization was first described more than 50 years ago as histologically 
altered epithelium surrounding tumors that were taken from the upper aerodigestive tract 
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(Slaughter et al., 1953). According to the field cancerization concept, multiple cell groups 
independently undergo neoplastic transformation under the stress of regional 
carcinogenic activity. Molecular genetic approaches have challenged the notion that 
independent transforming events are common in the epithelium of patients with HNSCC. 
Indeed, when a primary HNSCC is compared with a second tumor elsewhere in the 
respiratory tract, the paired tumors often harbor identical patterns of genetic alterations 
(Bedi et al., 1996; Worsham et al., 1995). Presumably, a critical genetic alteration in a 
single cell provides a growth advantage over its neighboring cells. At some point after 
transformation, cells harboring these early genetic alterations migrate to populate 
contiguous tracts of mucosa, accumulate other alterations, acquire additional growth 
advantages, and ultimately transform into aggressive subclones separated by time and 
space (Califano et al., 2000). Several reports have demonstrated that the epithelium of the 
upper respiratory tract may become populated by these clones of genetically damaged 
cells despite the lack of histopathologic evidence of dysplasia (Mao et al., 1996; Westra 
and Sidransky, 1998). The presence of morphologically intact but genetically damaged 
cells not only explains the phenomenon of field cancerization, but accounts for certain 
patterns of tumor behavior, such as local tumor recurrence following complete surgical 
resection, since pre-malignant or malignant clones have the ability to migrate and persist 
outside the filed of treatment. Future studies to refine the relationship among these 
lesions is needed to identify key molecular alterations that can be used as targets for 
therapy (Ha and Califano, 2003). 
Metastases arise following the spread of cancer from a primary site and the 
formation of new tumors in distant organs. At least 50% of patients with locally advanced 
 6
HNSCC develop locoregional or distant metastases, which are usually detected within the 
first 2 years of treatment (Argiris et al., 2008). When cancer is detected at an early stage, 
before it has spread, it can often be treated successfully by surgery or local irradiation, 
and the patient is frequently cured. However, when the cancer is detected after it is 
known to have metastasized, treatments are much less successful. Furthermore, for many 
patients in whom there was no evidence of metastasis at the time of their initial diagnosis, 
metastases can be detected at a later time. The metastatic process consists of a series of 
steps. As a primary tumor grows, it needs to develop a blood supply that can support its 
metabolic needs, through a process called angiogenesis (Folkman, 1971; 2002). These 
new blood vessels can also provide an escape route by which cells can leave the tumor 
and enter into the circulatory blood system (Wyckoff et al., 2000). Tumor cells might 
also enter the blood circulatory system indirectly via the lymphatic system (Stacker et al., 
2002). The cells need to survive in the circulation until they can arrest in a new organ, 
extravasating from the circulation into the surrounding tissue. Once in the new site, cells 
initiate and maintain growth to form preangiogenic micrometastases. This growth is 
sustained by the development of new blood vessels in order for a macroscopic tumor to 




In the early seventies Judah Folkman proposed the hypothesis that tumor growth 
is angiogenesis-dependent (Folkman, 1971). In this revolutionary report, Folkman 
showed preliminary evidence that tumors could not enlarge beyond 1 to 2 millimeters in 
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diameter without recruiting new blood vessels. His hypothesis stated that tumors secrete a 
diffusible substance that could stimulate endothelial cell proliferation in host capillary 
blood vessels. This was also the first report to introduce the concept of a novel form of 
tumor dormancy caused by blockade of angiogenesis. Indeed, most of us harbor 
microscopic tumors in various organs throughout life, and the vast majority of these 
tumors never expand further (Black and Welch, 1993). They may contain up to 1 million 
tumor cells that are proliferating and undergoing apoptosis, but the microscopic tumors 
do not invade locally and do not metastasize. They remain nonangiogenic, dormant, and 
harmless (Folkman and Kalluri, 2004). In the event of a shift in the balance of 
proangiogenic and antiangiogenic proteins, the total output of these proteins renders the 
tumor mass proangiogenic, and the tumor is enabled to switch to an angiogenic 
phenotype (Almog et al., 2006; Hanahan and Folkman, 1996). After the angiogenic 
switch (Rastinejad et al., 1989), both benign and malignant tumors can expand their 
tumor mass. Malignant angiogenic tumors, however, invade locally, metastasize to 
remote sites, and are potentially lethal. In the absence of the angiogenic switch, even 
tumors that are malignant by all other criteria may be harmless to the host (O'Reilly et al., 
1994). Folkman's discovery that tumor growth is angiogenesis-dependent led to a 
profound paradigm shift in cancer therapy and cancer biology. Before his hypothesis, the 
cancer cell itself was the only target of cancer therapies. Now it is widely accepted that 
microvascular endothelial cells recruited by tumors are viable and effective therapeutic 
targets (Cao and Langer, 2008). 
The vascular endothelial growth factor (VEGF) family and the receptor tyrosine 
kinases are key mediators of proangiogenic effects in tumor angiogenesis. This family of 
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structurally related molecules includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and 
placental growth factor (PlGF) (Ferrara, 2002; Hicklin and Ellis, 2005). The major 
mediator of tumor angiogenesis is VEGF-A, referred to as VEGF, which is expressed as 
various isoforms due to alternative splicing that leads to 121-, 165-, 189- and 206-amino-
acid proteins. VEGF165 is the predominant isoform and is commonly overexpressed in a 
variety of human solid tumors. The VEGF ligands bind to and activate three structurally 
similar type III receptor tyrosine kinases, namely VEGFR1 (also known as FLT1), 
VEGFR2 (also known as KDR), and VEGFR3 (also known as FLT4). Each VEGF ligand 
has distinctive binding specificities for each of these tyrosine kinase receptors, which 
contributes to their diversity of function (Ellis and Hicklin, 2008). VEGF signals mainly 
through VEGFR2, which is expressed at elevated levels by endothelial cells engaged in 
angiogenesis and by circulating bone marrow-derived endothelial progenitor cells. The 
role of VEGFR1 is less clear. It binds VEGF with higher affinity than VEGFR2, but its 
signaling properties are weaker (Shibuya and Claesson-Welsh, 2006). VEGFR3 
preferentially binds VEGF-C and VEGF-D and its expression in the adult is primarily on 
lymphatic endothelial cells. More recent data has demonstrated the expression and 
function of VEGFR3 on vascular endothelial cells (Laakkonen et al., 2007). VEGFR3 is 
important in cardiovascular development and remodeling of primary vascular networks 
during embryogenesis, and has a crucial role in post-natal lymphangiogenesis (Alitalo 
and Carmeliet, 2002). The neuropilins (NP1 and NP2, also known as NRP1 and NRP2) 
act as co-receptors for the VEGFRs, increasing the binding affinity of VEGF (Bielenberg 
and Klagsbrun, 2007; Klagsbrun et al., 2002; Soker et al., 1998). NP1 and NP2 have been 
postulated to signal independently of their association with VEGFR tyrosine kinase 
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receptors, but the role of VEGF activation of NP-mediated signaling is not fully 
understood. In fact, recent studies suggest that dual targeting of the vasculature with 
antibodies to VEGF and NP1 is more effective than single-agent therapy (Batchelor et al., 
2007). Differences in VEGFR biology are important, as various VEGF-targeting 
approaches differ in their ability to block receptor function (Ellis and Hicklin, 2008). 
Most types of human cancer cells express elevated levels of VEGF, as a 
consequence of the numerous and diverse genetic and epigenetic ways in which VEGF 
can be induced (Kerbel and Folkman, 2002). Hypoxia is a characteristic of solid tumors 
and is an important inducer of VEGF. Its effect is mediated through the hypoxia-
inducible transcription factors 1α and 2α (Semenza, 2003). The VEGF action is 
attributed mainly to a paracrine mechanism, since tumor cells produce VEGF but do not 
respond to it directly due low levels of VEGF receptors. In contrast, endothelial cells 
engaged in angiogenesis express numerous VEGF receptors, but they produce very little 
or no detectable VEGF. It is now clear, however, that VEGF in amounts sufficient to 
drive tumor angiogenesis originates from various host cells in the body such as 
endothelial cells (Kaneko et al., 2007), platelets (Klement et al., 2009), muscle cells (Kut 
et al., 2007), and tumor-associated stromal cells (Liang et al., 2006). The fact that tumor 
cells of many types express VEGF receptors (especially VEGFR1) (Dallas et al., 2007; 
Dong et al., 2007; Fan et al., 2005; Kessler et al., 2007; Wey et al., 2005) and also 
produce VEGF, indicates that VEGF may act as an autocrine growth factor for tumor 
cells (Kerbel, 2008). Furthermore, it has been shown that VEGFR1 is expressed within 
the cell rather than on the surface of breast cancer cells, promoting cell survival by an 
intracrine mechanism (Lee et al., 2007b). In addition, it has been reported that very low 
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levels of autocrine VEGF mediate endothelial cell survival and vascular homeostasis by 
signaling through intracellular VEGFR2 (Lee et al., 2007a).  
Based on this knowledge, several angiogenesis inhibitors have been developed to 
target vascular endothelial cells and block tumor angiogenesis. Recent reports have also 
shown that inhibiting tumor angiogenesis increases the effectiveness of coadministered 
chemotherapy (Escudier et al., 2007a; Faivre et al., 2007; Hurwitz et al., 2004; Motzer et 




Targeting cells that support tumor growth rather than cancer cells themselves is a 
relatively new approach to cancer therapy. Endothelial cells are more stable genetically 
and therefore less likely to accumulate mutations that allow them to develop drug 
resistance (Kerbel and Folkman, 2002). In a human colorectal carcinoma, for example, it 
has been reported up to 11,000 total genomic alterations per tumor cell (Stoler et al., 
1999). In contrast, endothelial cells in a tumor bed reveal differences only in gene 
expression, but not genomic alterations (Folkman et al., 2000; St Croix et al., 2000). 
Angiogenesis inhibitors can act directly or indirectly. Direct angiogenesis 
inhibitors prevent vascular endothelial cells from proliferating, migrating, or avoiding 
cell death in response to a spectrum of pro-angiogenic proteins, including VEGF, basic 
fibroblast growth factor (bFGF), interleukin-8 (CXCL8), platelet-derived growth factor 
(PDGF), and platelet-derived endothelial growth factor (PD-EGF). Tumors treated with 
direct angiogenesis inhibitors are less likely to acquire drug resistance (Boehm et al., 
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1997; Kerbel, 1991). Indirect angiogenesis inhibitors generally prevent the expression or 
the activity of a tumor protein that activates angiogenesis, or block the expression of its 
receptor on endothelial cells. Many of these tumor cell proteins are the products of 
oncogenes that drive the angiogenic switch (Kerbel et al., 1998; Rak et al., 2002). 
In 2004, the U.S. Food and Drug Administration (FDA) approved the first 
antiangiogenic drug for cancer treatment in combination with conventional 
chemotherapy: bevacizumab (Avastin®). Bevacizumab was the first angiogenesis 
inhibitor proven to delay tumor growth and, more importantly, increased the overall 
survival of patients. Phase III clinical trials for patients with metastatic colorectal cancer 
demonstrated improved response rates, increased progression-free survival and increased 
overall survival when bevacizumab was added to irinotecan and 5-fluorouracil (Hurwitz 
et al., 2004). A survival benefit from bevacizumab in combination with chemotherapy 
has also been observed in patients with advanced non-small cell lung cancer (Manegold, 
2008; Sandler et al., 2006), metastatic breast cancer (Miller et al., 2005) and metastatic 
renal cell carcinoma (Escudier et al., 2007b). Additionally, single agent bevacizumab led 
to an increase of time to tumor progression in advanced renal cell cancer (Yang, 2004). 
Several other clinical trials are currently underway to investigate the activity of this agent 
in various other cancer types. A recent phase I study in which bevacizumab was used in 
combination with fluorouracil/hydroxyurea/radiation therapy showed anti-tumor activity 
in HNSCC patients (Seiwert et al., 2008).  
There are currently eight FDA approved anticancer therapies with recognized 
antiangiogenic properties, comprising two primary categories: 1) monoclonal antibodies 
directed against specific proangiogenic growth factors and/or their receptors; and 2) small 
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molecule tyrosine kinase inhibitors (TKIs) of multiple proangiogenic growth factor 
receptors. Inhibitors of mammalian target of rapamycin (mTOR) represent a third, 
smaller category of antiangiogenic agents. In addition, at least two other approved 
angiogenic agents may indirectly inhibit angiogenesis through mechanisms that are not 
completely understood. 
Four monoclonal antibody therapies are approved to treat several tumor types: 
Bevacizumab (Avastin®), cetuximab (Erbitux®), panitumumab (Vectibix™), and 
trastuzumab (Herceptin®). Bevacizumab is a humanized monoclonal antibody that binds 
biologically active forms of VEGF and prevents its interaction with VEGFR1 and 
VEGFR2, thereby inhibiting endothelial cell proliferation and angiogenesis (Hicklin and 
Ellis, 2005). The approved indications for bevacizumab are metastatic colorectal cancer, 
non-small cell lung cancer, and advanced breast cancer. Cetuximab is a chimeric IgG1 
monoclonal antibody that binds the extracellular domain of EGFR, preventing ligand 
binding and activation of the receptor. This blocks downstream signaling of EGFR, 
inhibiting cell proliferation and angiogenesis. Cetuximab was the first targeted agent 
proved to be clinically effective in combination with radiation therapy for patients with 
locally advanced HNSCC (Bonner et al., 2006; Choong and Cohen, 2006; Harari and 
Huang, 2006; Harari et al., 2009; Le Tourneau and Siu, 2008). Cetuximab is also 
approved for use in metastatic colorectal cancer. Panitumumab is a fully humanized IgG2 
anti-EGFR monoclonal antibody, also approved for use in metastatic colorectal cancer. 
Trastuzumab is a humanized IgG1 monoclonal antibody that binds the extracellular 
domain of HER-2, which is overexpressed in 25-30% of invasive breast cancer tumors. 
Three small molecule tyrosine kinase inhibitors are currently approved as 
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anticancer therapies: Erlotinib (Tarceva®), sorafenib (Nexavar®), and sunitinib 
(Sutent®). Erlotinib inhibits EGFR and is indicated for the treatment of non-small cell 
lung cancer and pancreatic cancer. Sorafenib inhibits VEGFR1, VEGFR2, VEGFR3, 
PDGFR-β, and Raf-1; and it is approved for treatment of advanced hepatocellular and 
renal-cell carcinoma (Escudier et al., 2007a). Sunitinib inhibits VEGFR1, VEGFR2, 
VEGFR3, PDGFR-β, and RET; and its indications are advanced renal-cell carcinoma and 
gastrointestinal stromal tumor (Motzer et al., 2007b). 
One mTOR inhibitor is currently approved as anti-cancer therapy. Temsirolimus 
(Torisel®) is a small molecule inhibitor of PI3K/Akt/mTOR pathway involved in tumor 
cell proliferation and angiogenesis, and is approved for treatment of advanced renal cell 
carcinoma (Hudes et al., 2007; Motzer et al., 2007a). 
Most recently, two drugs were approved as cancer therapies for multiple myeloma 
and mantle cell lymphoma. First, bortezomib (Velcade®) is a proteasome inhibitor that 
disrupts signaling of the cancer cell, leading to cell death and tumor regression, and may 
have indirect antiangiogenic properties (Ma and Adjei, 2009). Lastly, thalidomide 
(Thalomid®) possesses immunomodulatory, anti-inflammatory, and antiangiogenic 
properties (Breitkreutz and Anderson, 2008). The precise mechanisms of action of these 
two drugs are also not fully understood. 
Despite all the advances in antiangiogenic therapies, several challenges still 
remain. The survival benefits of these treatments are relatively modest, usually measured 
in months (Kerbel, 2008). In addition, the treatments are extremely expensive (Berenson, 
2006; Schrag, 2004) and have significant side effects (Eskens and Verweij, 2006; 
Verheul and Pinedo, 2007). Although promising results have been obtained with 
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antiangiogenic therapies in phase II trials (Fujita et al., 2007; Liang et al., 2008), 
cetuximab is the only agent proved by phase III clinical trials to improve survival, either 
in combination with radiation therapy or in first-line treatment for recurrent or metastatic 
HNSCC. Cetuximab was approved by the FDA in 2006, and constitutes the only targeted 
therapy available for this malignancy (Bozec et al., 2009; Le Tourneau and Siu, 2008). 
Discovery of novel molecular targets, and the inclusion of these agents in combined 
treatment regimes, is likely to increase therapeutic efficacy.  Therefore, understanding of 
the molecular mechanisms involved in the development and progression of HNSCC may 
help to identify better tractable targets for pharmacological intervention in this disease.  
 
Signaling pathways and molecular targeted therapy 
 
The aberrant expression and function of molecules regulating cell signaling, 
growth, survival, motility, cell cycle, and angiogenesis underlie the progressive 
acquisition of a malignant phenotype in HNSCC (Molinolo et al., 2009). Key signaling 
networks deregulated in HNSCC include, among others: the EGFR (Dietz et al., 2008; 
Pomerantz and Grandis, 2003), the transcription factor signal transducer and activator 
transcription 3 (STAT3) (Grandis et al., 1998; Leeman et al., 2006), the 
phosphatidylinositol-3-kinase (PI3K)/Akt (Moral and Paramio, 2008), and the mitogen 
activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways 
(Mishima et al., 2002; Zhang et al., 2004). 
Many human cancers express high levels of growth factors and corresponding 
receptors, and many malignant cells exhibit highly active receptor tyrosine kinases due to 
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their activation by an autocrine or paracrine mechanism. Among the best-studied group 
of these receptors is the EGFR family (also known as type I receptor tyrosine kinases or 
ErbB tyrosine kinase receptors), which is essential for numerous normal cellular 
processes. The aberrant activity of this receptor family has also been linked to the 
development and growth of numerous tumor types including 80 to 90% of all HNSCC 
(Grandis and Tweardy, 1993). Indeed, EGFR overexpression may represent an 
independent prognostic marker correlating with increased tumor size, decreased radiation 
sensitivity, and increased risk of recurrence (Ang et al., 2002; Gupta et al., 2002). 
Constitutive EGFR activation in HNSCC is also caused by its autocrine stimulation 
through the co-expression of EGFR with one of its ligands, transforming growth factor-α 
(TGFα), which is frequently observed in HNSCC and correlates with a poor prognosis 
(Quon et al., 2001). The presence of truncated mutant forms of EGFR, which causes its 
constitutive activation, has also been detected in some HNSCC cases and may be 
resistant to EGFR target therapy (Sok et al., 2006). Interestingly, G protein-coupled 
receptor (GPCR)-induced cleavage of EGF-like growth factors leads to EGFR 
transactivation and EGFR-related signaling in cancer cells, suggesting that GPCR–EGFR 
cross-communication may play a role in the development and progression of HNSCC and 
other human cancers (Dorsam and Gutkind, 2007). Once activated, EGFR stimulates a 
number of downstream signaling events that contribute to normal and aberrant cell 
growth. Among them, EGFR activates the STAT3, the PI3K/Akt, and the MAPK/ERK 
pathways, which in turn contribute to the malignant growth and metastatic potential of 
HNSCC (Molinolo et al., 2009). 
Currently, seven STAT family members have been identified, STAT 1, 2, 3, 4, 5a, 
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5b and 6, which participate in the transcription of genes involved in immune responses, 
growth, and cell fate decisions (Darnell, 2002). While STAT activity is essential for 
normal cellular functions, deregulation of the STAT pathway contributes to a number of 
human diseases. Indeed, gain of function of STATs is often associated with cellular 
transformation and oncogenic potential (Reich and Liu, 2006). Cytokines and growth 
factors stimulate STAT proteins by acting on their cognate receptors, which leads to the 
recruitment and phosphorylation of Janus kinase 1 and 2 (JAK-1 and JAK-2) that in turn 
phosphorylate STAT proteins at specific tyrosine residues, leading to the formation of 
homo- and heterodimers. STAT dimers translocate to the nucleus where they bind to 
consensus DNA sequences and activate the expression of growth promoting genes (Reich 
and Liu, 2006). Constitutive activation of STAT3 has been demonstrated in many 
cancers, including breast cancer, leukemia, lymphoma, lung, and thyroid cancers 
(Bromberg, 2002; Darnell, 2005). Notably, early studies indicated that HNSCC also 
exhibit remarkably elevated levels of the phosphorylated active forms of STAT3 
(Grandis et al., 1998). Moreover, studies have shown that blockade of STAT3 activity 
leads to growth inhibition of HNSCC, supporting the importance of signaling through 
STAT3 in HNSCC (Grandis et al., 1998; Grandis et al., 2000; Rubin Grandis et al., 
2000). Elevated levels of STAT3 alter cell cycle progression, and promote the 
proliferation and survival of HNSCC cells (Leeman et al., 2006). In fact, STAT3 
activation may represent an early event in oral carcinogenesis, as both tumor and the 
adjacent normal epithelia of HNSCC patients show higher levels of STAT3 expression 
and phosphorylation (Grandis et al., 2000). Activated STAT3 also correlates with lymph 
node metastasis and poor prognosis (Grandis et al., 1998; Leeman et al., 2006). Many 
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mechanisms may converge to promote the persistent activation of STAT3 in HNSCC. 
While the direct activation of STAT3 by EGFR has been clearly shown in HNSCC cells 
(Grandis et al., 1998; Leeman et al., 2006), STAT3 can also be activated by an EGFR-
independent mechanism (Sriuranpong et al., 2003). This mechanism often involves the 
autocrine activation of the gp130 cytokine receptor in HNSCC cells by tumor-released 
cytokines such as interleukin-6 (IL-6), which activates STAT3 independently from the 
activation status of EGFR. Furthermore, interfering with this cytokine-initiated pathway 
of STAT3 activation can result in the reduced growth and apoptotic death of HNSCC 
cells (Sriuranpong et al., 2003). Other cytokines and growth factors, such as 
erythropoietin (Lai et al., 2005), growth hormone (Gronowski et al., 1995), TGF-α 
(Grandis et al., 1998), thrombopoietin (Gurney et al., 1995), and PDGF (Vignais et al., 
1996) have been demonstrated to stimulate STAT3 in HNSCC and other malignancies 
(Aggarwal et al., 2006). Several therapeutic approaches are being developed to block 
STAT3, which may prove to be an efficacious treatment for HNSCC (Leeman et al., 
2006). 
The PI3K/Akt signaling is one of the most frequently targeted pathways in human 
cancers, since deregulation in any component of PI3K leads to tumorigenesis (Cully et 
al., 2006). Genomic aberrations in the PI3K components include mutation, amplification, 
and/or rearrangements, which result in deregulated cell growth control and survival. 
These alterations contribute to a competitive growth advantage, metastatic potential, and 
resistance to therapy (Hennessy et al., 2005). The direct product of PI3K activity, the 
lipid second messenger PtdIns(3,4,5)P3 (PIP3), is a constituent of the inner leaflet of the 
plasma membrane and serves as docking sites for proteins including Akt. The Akt family 
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of kinases consists of three members (Akt1, Akt2 and Akt3), which possess conserved 
phosphorylatable threonine and serine residues (T308 and S473) that are critical for Akt 
function (Cantley, 2002). Akt is a central regulator of widely divergent cellular processes 
including proliferation, differentiation, migration, survival, and metabolism (Tokunaga et 
al., 2008). The importance of Akt in cancer is underscored by the fact that many 
oncogenic mutations result in the constitutive activation of Akt, and that many tumor 
suppressor proteins act by inhibiting the activity of Akt and its downstream targets (Luo 
et al., 2003; Vivanco and Sawyers, 2002). Recent reports support the importance of Akt 
in HNSCC. Akt has been shown to be persistent activated in HNSCC, and blockade of 
PDK1, which acts upstream of Akt, has been demonstrated to inhibit tumor cell growth 
(Amornphimoltham et al., 2004; Patel et al., 2002). Moreover, Akt is detected in nearly 
50% of tongue preneoplastic lesions, and its activation represents an independent 
prognostic marker of poor clinical outcome in tongue and oropharyngeal HNSCC 
(Massarelli et al., 2005; Yu et al., 2007). Multiple genetic and epigenetic events may 
converge to promote the activation of the PI3K/Akt pathway in HNSCC, including EGFR 
overexpression, Ras mutations, PI3K gene amplification, and defective PTEN activity. 
Indeed, the presence of multiple convergent pathways resulting in enhanced Akt function 
may explain why activation of the Akt pathway represents one of the most frequent 
events in HNSCC (Molinolo et al., 2007; Molinolo et al., 2009). 
Several agents have been developed to target the MAPK pathway for cancer 
treatment, based on its aberrant activity in tumor cells (Sebolt-Leopold and Herrera, 
2004). The MAPK cascade is a key intracellular signaling pathway that regulates diverse 
cellular functions including cell proliferation, cell cycle regulation, cell survival, 
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angiogenesis, and cell migration. The MAPK pathway is generally described as a linear 
cascade of events initiated by receptor tyrosine kinases at the cell surface and culminates 
in the regulation of gene transcription in the nucleus. These cascades are comprised of 
three protein kinases controlled by protein phosphorylation: a MAPK kinase kinase 
(MAPKKK), a MAPK kinase (MAPKK), and a MAPK (Johnson and Lapadat, 2002). 
The terminal serine/threonine kinases (MAPKs) are the ERK1/2 (p44 ERK1 and p42 
ERK2), the c-Jun amino-terminal kinases (JNK1/2/3), and p38 kinases. Generally, the 
ERK pathway is activated by growth factor-stimulated cell surface receptors tyrosine 
kinases that are important in cancer biology, such as EGFR, PDGFR, and VEGFR 
(Roberts and Der, 2007); whereas the JNK and p38 pathways are activated by stress (UV 
light, osmotic stress, γ-irradiation, heat shock, and growth factor withdraw) and cytokines 
(TNF-α and IL-1) (Raingeaud et al., 1995; Xia et al., 1995). The role of ERK pathway in 
tumorigenesis is well established because of its critical involvement in the regulation of 
cell proliferation and survival, making ERK a focus of intense investigation for 
therapeutic targeting (Benson et al., 2006). On the other hand, JNK and p38 inhibitors are 
mainly studied as a therapy for inflammatory diseases (Dominguez et al., 2005; Hynes 
and Leftheri, 2005), although JNK inhibitors have also been explored for the treatment of 
vascular, neurodegenerative, metabolic, and oncological diseases (Manning and Davis, 
2003). During the past few years, the understanding of the Ras/Raf/MEK/ERK signaling 
in HNSCC has increased (Das et al., 2000; Mishima et al., 2002; Yamatodani et al., 2009; 
Zhang et al., 2008); therefore, molecular therapies targeting MAPK/ERK are likely to 
emerge for the treatment of HNSCC.  
 In summary, the knowledge of the complex signaling network in cancer has 
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increased significantly leading to the discovery of novel molecular targets for drug 
development. Emphasis is given on targeting multiple signaling pathways for more 
effective disease management. Therefore, a better understanding of the crosstalk between 
signaling pathways involved in HNSCC will provide the opportunity for the development 
of novel strategies for targeting multiple molecular components for more effective 
prevention and treatment of HNSCC (Matta and Ralhan, 2009). 
 
Cytokines and growth factors 
 
Cytokines and growth factors play pivotal roles in a variety of biological 
responses, including the immune response, hematopoiesis, neurogenesis, embryogenesis, 
and oncogenesis (Heldin, 1995; Hibi and Hirano, 1998; Hirano, 1998; Hunter, 1997). 
They exert their effects through specific receptors, and activate several signaling 
pathways through distinct regions of each receptor’s cytoplasmic domain, including 
STAT3, PI3K, and MAPK (Birge et al., 1996; Darnell, 1997; Heldin, 1995; Heldin et al., 
1997; Hirano et al., 1997; Hunter, 1997; Ihle, 1996; Taniguchi, 1995).  
Cytokines are low molecular weight, soluble proteins, that generally act over 
short distances, within narrow time frames at very low concentrations and must therefore 
be produced de novo in response to a stimulus (Pries and Wollenberg, 2006). They are 
known to possess pleiotropic as well as redundant characteristics, which means that a 
particular cytokine can influence various cell types as well as different cytokines can 
share the same function. Furthermore cytokines are able to function in an antagonistic or 
synergistic manner by inhibiting or stimulating particular functions of other cytokines, 
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respectively. Thus, a highly complex network of cytokine interactions exists in vivo 
(Rakesh and Agrawal, 2005; Taniguchi, 1995).  
Cytokines and growth factors are produced by various cell types including cells of 
the immune system, endothelial cells, epithelial cells, and fibroblasts, and deregulation in 
this network lead to several diseases (Bendall, 2005; Yan et al., 2006). HNSCC cells 
develop molecular strategies in order to evade growth inhibitory effects of cytokines 
present in the tumor microenvironment; thus, the malignant transformation process is 
strongly associated with an altered response to cytokine stimulation (Douglas et al., 2004; 
Pries and Wollenberg, 2006). Several cytokines and growth factors are highly secreted in 
HNSCC including IL-4, IL-6, IL-8 (CXCL8), IL-10, prostaglandin E2 (PGE2), 
granulocyte macrophage-colony-stimulating factor (GM-CSF), VEGF, EGF, and bFGF 
(Chen et al., 1999; Eisma et al., 1997; Mann et al., 1992; Wilson et al., 2009). 
IL-6 is a multifunctional cytokine that is important for immune responses, cell 
survival, apoptosis, and proliferation (Kishimoto, 2005), and it plays an important role in 
the pathophysiology of cancer (Hodge et al., 2005). IL-6 signals via a heterodimeric IL-
6R/gp130 complex, whose engagement triggers mainly the activation of JAK/STAT 
pathway, although it can also activate PI3K/Akt and Ras/MAPK (Kishimoto, 2005). 
Several studies describe a tumorigenic role of IL-6 and its major effector, STAT3, in 
many cancers, including breast, lung, colon, prostate, ovarian, melanoma, and 
hematological cancers (Hodge et al., 2005). Notably, recent studies have demonstrated a 
correlation between high levels of IL-6 and poor prognosis of HNSCC patients 
(Chakravarti et al., 2006; Duffy et al., 2008; Kanazawa et al., 2007; Riedel et al., 2005). 
In addition, IL-6 has been shown to directly influence the proliferation and the invasion 
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potential of HNSCC cells (Kanazawa et al., 2007). Given the importance of IL-
6/gp130/IL-6R/STAT3 signaling in HNSCC, IL-6 may be an attractive target for HSCCC 
therapy. 
Chemokines compose a large family of inflammatory cytokines. CXCL8 is a 
chemokine of the Glu-Leu-Arg (ELR)+ CXC family with potent angiogenic effects 
(Strieter et al., 2006). CXCL8 activates multiple intracellular signaling pathways 
downstream of two cell-surface, G protein-coupled receptors, CXCR1 and CXCR2 
(Holmes et al., 1991; Murphy and Tiffany, 1991). Increased expression of CXCL8 and/or 
its cognate receptors has been characterized in cancer cells, endothelial cells, infiltrating 
neutrophils, and tumor-associated macrophages, suggesting that CXCL8 may function as 
a significant regulatory factor within the tumor microenvironment (Waugh and Wilson, 
2008). CXCL8 has been demonstrated to activate PI3K/Akt (Cheng et al., 2008), 
MAPK/ERK (Venkatakrishnan et al., 2000), and STAT3 (Burger et al., 2005) pathways. 
As a consequence of the diversity of effectors and downstream targets, CXCL8 signaling 
promotes angiogenic responses in endothelial cells, increases proliferation and survival of 
endothelial and cancer cells, and potentiates the migration of cancer cells, endothelial 
cells, and infiltrating neutrophils at the tumor site (De Larco et al., 2004; Li et al., 2003). 
Accordingly, CXCL8 expression correlates with the angiogenesis, tumorigenicity, and 
metastasis of tumors in numerous xenograft and orthotopic in vivo models (Bendre et al., 
2005; Huang et al., 2002; Inoue et al., 2000; Karashima et al., 2003). Thus, inhibiting the 
effects of CXCL8 signaling may be a significant therapeutic intervention in targeting 
HNSCC.  
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In addition to cytokines, growth factors represent a subset of extracellular stimuli 
from the surrounding microenvironment that regulates cell proliferation, differentiation, 
migration, and survival. Soluble growth factor peptide ligands bind to their cognate 
receptors and initiate a cascade of intracellular events. Epidermal growth factor (EGF) is 
the prototypic member of the EGF family, and is a key regulatory factor in promoting cell 
survival (Jost et al., 2000). EGF binds to a family of receptors (ErbB receptor family) and 
illicits specific cellular response through signal transduction pathways. These signaling 
pathways are regulated by the amount of EGF present, the expression level of ErbB 
receptors, and the presence of both positive and negative signaling regulators, indicating 
the complexity and specificity of EGF signaling (Burgess et al., 2003; Herbst, 2004). The 
ErbB family consists of four closely related tyrosine kinase transmembrane receptors: 
ErbB1/EGFR, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4 that sense their 
microenvironment by binding to an array of extracellular ligands (Normanno et al., 
2005). EGF binds exclusively to EGFR, which forms homo- or heterodimers with the 
other three ErbB receptors (Muthuswamy et al., 1999; Olayioye et al., 2000). This 
dimerization activates the tyrosine kinase domain through phosphorylation of the 
receptors, which ultimately leads to phosphorylation of serine or threonine residues on 
other protein kinases and/or transcription factors (Olayioye et al., 2000). This kinase 
cascade leads to amplification of a network of signaling pathways resulting in changes in 
protein function and activation of gene transcription (Henson and Gibson, 2006). Among 
the signaling pathways activated by EGF signaling are STAT3 (Leaman et al., 1996), 
PI3K/Akt (Gibson et al., 2002), and MAPK/ERK (Johnson et al., 2005). In cancer, 
intracellular signaling pathways regulated by EGF are often altered. The constitutively 
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activated STAT3 in cancer cells is mainly attributed to deregulation of upstream 
pathways, such as activation of EGFR, which elevates EGF-induced transcriptional 
activity, and cell survival (Olayioye et al., 1999). EGF-mediated deregulation of the 
PI3K/Akt pathway is present in approximately 25% of solid tumors (Sansal and Sellers, 
2004). Moreover, EGF-mediated activation of ERK signaling is deregulated through 
mutations in Ras in many cancers (Duursma and Agami, 2003). Since the EGF signaling 
network can be deregulated at many levels during cancer progression, it also makes the 
EGF pathway a potential target for HNSCC therapy. 
The understanding of the complex network and interaction of cytokines, 
chemokines, and growth factors in HNSCC may provide new therapeutic targets for the 
treatment of HNSCC patients. Cells from the tumor microenvironment play a key role in 
the malignant progression since they secrete high levels of cytokines and growth factors, 




Increasing evidence shows that the interaction between cancer cells and the 
surrounding stroma is a critical factor in tumor growth (Anton and Glod, 2009). As the 
understanding of cancer biology continues to expand, there is a tendency to treat tumors 
as a functional organ, composed of various cell types and molecules that interact in a 
dynamic and interdependent manner. The recognition of the tumor as a complex organ 
may lead to more specific and elegant methods of treating cancer that may minimize 
toxicity and improve patient survival (Hanna et al., 2009).  
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In addition to tumor cells, the tumor microenvironment is composed of 
endothelial cells, pericytes, invading inflammatory cells and leucocytes, fibroblasts, and 
extracellular matrix (ECM) components. Recent studies demonstrated that the tumor 
stroma does not exist simply as a passive support structure, but rather plays an active role 
in tumor progression (Blavier and Declerck, 2005; Derynck et al., 2001; Shekhar et al., 
2001). In fact, the activation of autocrine and paracrine signaling pathways by stroma-
derived cytokines and growth factors has been implicated in promoting tumor cell 
proliferation and metastasis (Aharinejad et al., 2009). Therefore, elements of the tumor 
microenvironment are promising targets for novel therapies that may overcome many of 
the limitations of current treatment options that are primarily targeted to the cancer cell. 
Combinatorial therapy that targets multiple components of the tumor microenvironment 
may allow for lower doses of each individual agent, and may overcome compensatory 
escape mechanisms that tumors usually rely upon for survival (Blansfield et al., 2008; 
Dorrell et al., 2007; Mizukami et al., 2005). In addition, anticancer agents directed at the 
tumor stroma, which is genetically more stable than tumor cells themselves, may exhibit 
less associated toxicity and drug resistance (Hanna et al., 2009). Although, recent studies 
in several experimental models suggest that both tumor and stromal cells may be 
involved in the reduced responsiveness to the treatments, as a consequence of acquired 
resistance to antiangiogenic drugs, similar to other anticancer therapies (Shojaei and 
Ferrara, 2008). 
Several unique targets for cancer therapy are present in the tumor 
microenvironment. Recent studies of endothelial cells (Arap et al., 2002; Benezra et al., 
2001; Hoffman et al., 2003; Joyce et al., 2003; Trepel et al., 2002), and stromal 
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fibroblasts (Bhowmick et al., 2004a; Bhowmick et al., 2004b; Park et al., 1999) have 
identified molecular differences between nontumor cells in the microenvironment of 
preneoplastic lesions compared to tumors. These proteins themselves could be 
therapeutically targeted or used as “zip codes” to specifically deliver drugs to these cells. 
Thus, targeting selectively modified cells in the tumor microenvironment, would not 
affect their unmodified precursors in normal tissues (Joyce, 2005). Finally, the ultimate 
goal of targeting tumor-stroma interactions is to develop improved therapies that translate 
into prolonged survival for the HNSCC patients (Hanna et al., 2009). 
 
Statement of purpose 
 
More than half a million new cases of HNSCC are diagnosed each year 
worldwide. Despite extensive basic and clinical research, the 5-year survival rate for 
these patients is 50%, one of the lowest among major cancers, and has not improved 
significantly over the past three decades. Molecular targeted therapy is a promising 
approach to treat HNSCC, and it has been shown to improve overall patient survival. 
Although recent drugs are proven to have a positive effect in the treatment of cancer, the 
benefits are still modest, the prices are extremely high, these agents have many side 
effects, and the tumors may acquire drug resistance. Therefore, discovery of novel 
therapeutic targets may improve clinical outcomes specially if combined with existing 
therapies. 
Tumor angiogenesis is crucial for cancer progression and requires active 
interaction between endothelial cells and tumor cells. It is well established that cancer 
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cells secrete angiogenic factors to recruit and sustain tumor vascular networks. However, 
little is known about the effect of endothelial cell-secreted factors on the phenotype and 
behavior of tumor cells. The identification and characterization of the signaling events 
initiated by tumor-associated endothelial cells may have important implications in cancer 
therapy. Emerging knowledge has shed light on signaling cascades that regulate HNSCC 
progression. Among them, STAT3, PI3K/Akt, and MAPK/ERK pathways are known to 
play critical roles in the control of cell cycle, survival, proliferation, and migration of 
tumor cells. However, the impact of endothelial cell-initiated signaling on the activation 
of the STAT3, Akt, and ERK pathways in HNSCC is unclear. In this dissertation we will 
explore molecular signaling events in HNSCC cells initiated by endothelial cells and the 
biological effects of this crosstalk. 
In chapter II, we demonstrated that factors secreted by endothelial cells namely 
IL-6, CXCL8, and EGF activate STAT3, Akt, and ERK signaling pathways in HNSCC 
cells, increasing tumor cell survival and migration. In chapter III we explored in more 
depth this network of signaling events in HNSCC initiated by endothelial cells. More 
specifically, we demonstrated that downregulation of IL-6 in tumor-associated 
endothelial cells is sufficient to inhibit tumor growth.  
 
Hypothesis 
The central hypothesis addressed in this dissertation is that factors secreted by 
endothelial cells initiate signaling pathways in head and neck squamous cell carcinoma 




This central hypothesis will be tested by addressing the following specific aims: 
- Specific Aim 1: To evaluate the impact of endothelial cell-secreted factors on the gene 
expression profile of head and neck squamous cell carcinoma cells. 
- Specific Aim 2: To study molecular signaling events initiated by endothelial cells that 
result in the activation of STAT3, Akt, and ERK signaling pathways in head and neck 
squamous cell carcinoma cells. 
- Specific Aim 3: To study the effect of endothelial cell-derived IL-6 on head and neck 
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CROSSTALK INITIATED BY ENDOTHELIAL CELLS ENHANCES 
MIGRATION AND INHIBITS ANOIKIS OF SQUAMOUS CELL CARCINOMA 




It is well known that cancer cells secrete angiogenic factors to recruit and sustain 
tumor vascular networks. However, little is known about the effect of endothelial cell-
secreted factors on the phenotype and behavior of tumor cells. The hypothesis underlying 
this study is that endothelial cells are able to initiate signaling pathways in tumor cells. 
Here, we observed that soluble mediators from primary human dermal microvascular 
endothelial cells (HDMEC) induce phosphorylation of STAT3, Akt, and ERK in a panel 
of head and neck squamous cell carcinoma (HNSCC) cells (OSCC3, UM-SCC-1, UM-
SCC-17B, UM-SCC-74A). Gene expression analysis demonstrated that interleukin-6 (IL-
6), interleukin-8 (CXCL8), and epidermal growth factor (EGF) are upregulated in 
endothelial cells co-cultured with HNSCC. Blockade of endothelial cell-derived IL-6, 
CXCL8, or EGF by gene silencing or with neutralizing antibodies inhibited the activation 
of STAT3, Akt, and ERK in tumor cells, respectively. It has been demonstrated that Bcl-
2 is upregulated in tumor microvessels in patients with HNSCC. Here, we observed that 
Bcl-2 signaling induces expression of IL-6, CXCL8, and EGF, providing a mechanism 
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for the upregulation of these cytokines in tumor-associated endothelial cells. This study 
expands the contribution of endothelial cells to the pathobiology of tumor cells. It unveils 
a new mechanism in which endothelial cells function as the initiators of a molecular 




Tumor angiogenesis requires active interaction between endothelial and tumor 
cells, and plays an important role in cancer progression (Folkman, 2002). However, 
emphasis has been placed on the assumption that tumor cell-initiated signals are the 
dominant events in tumor angiogenesis and tumor growth. Recent studies have 
demonstrated signaling crosstalks between tumor cells and endothelial cells that promote 
tumor growth. In cell contact-dependent interactions, Jagged1 expressed by squamous 
cell carcinoma (SCC) cells activates Notch signaling in adjacent endothelial cells and 
enhances tumor growth (Zeng et al., 2005). In a cell contact-independent system, vascular 
endothelial growth factor (VEGF) secreted by tumor-associated endothelial cells induces 
Bcl-2, growth-related oncogene (GRO)-α (CXCL1), and interleukin-8 (CXCL8) 
expression in SCC cells (Kaneko et al., 2007). Notably, these endothelial cell-initiated 
signals significantly enhanced tumor growth in vivo (Kaneko et al., 2007). Collectively, 
this work indicates that the impact of endothelial cells in the pathobiology of cancer is 
not limited to making angiogenic blood vessels in response to tumor cell-initiated signals. 
The identification and characterization of the signaling events initiated by tumor-
associated endothelial cells may have important implications in human cancer therapy.  
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Squamous cell carcinoma is a common cancer in the gastro-intestinal track, lung, 
skin, and head and neck region. For example, more than 500,000 new patients with head 
and neck squamous cell carcinomas (HNSCC) are diagnosed each year worldwide (Chin 
et al., 2006; Jemal et al., 2008). The 5-year survival rate for patients with HNSCC is one 
of the lowest among major cancer sites, and has not improved significantly over the last 
30 years despite extensive basic and clinical research (Forastiere et al., 2001; Jemal et al., 
2008; Mao et al., 2004). Today, we know that several intracellular signaling molecules 
are key orchestrators of SCC progression. Among them, the signal transducer and 
activator of transcription 3 (STAT3) has been described to be constitutively active in 
HNSCC and in several other epithelial malignancies (Grandis et al., 1998; Leeman et al., 
2006). Altered expression or mutation of components of the phosphoinositol 3-kinase 
(PI3K)/Akt pathway has also been implicated in tumorigenesis (Luo et al., 2003; Vivanco 
and Sawyers, 2002). In addition, the mitogen-activating protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK) pathway has been described as an important 
regulator of tumor growth and a key target for cancer therapy (Friday and Adjei, 2008; 
Roberts and Der, 2007). These three signaling molecules, i.e. STAT3, Akt, and ERK, 
play critical roles in the control of cell cycle, survival, proliferation, and migration of 
tumor cells. Notably, deregulation of any of these pathways has been shown to drive 
oncogenic transformation (Chang et al., 2003; Song and Grandis, 2000; Zeng et al., 
2002). However, the impact of endothelial cell-initiated signaling on the activation of 
STAT3, Akt, and ERK signaling in tumor cells is unclear.  
It is known that vascular endothelial growth factor (VEGF) induces Bcl-2 
expression in endothelial cells, and that Bcl-2 expression level in tumor-associated 
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endothelial cells is directly correlated with tumor angiogenesis and tumor growth 
(Kaneko et al., 2007; Nor et al., 1999; Nor et al., 2001a). Notably, Bcl-2 gene expression 
is approximately 60,000-fold higher in the endothelial cells lining tumor blood vessels in 
patients with HNSCC, as compared to the endothelial cells from normal oral mucosa 
(Kaneko et al., 2007). It is also known that Bcl-2 induces CXC chemokines expression by 
endothelial cells, which results in enhanced HNSCC invasiveness and local recurrence 
(Karl et al., 2005; Warner et al., 2008). It has been shown that Bcl-2 signals through 
nuclear factor kB (NF-kB) to induce CXCL1 and CXCL8 expression in endothelial cells 
(Karl et al., 2005). However, the effect of Bcl-2 in the expression of IL-6 (known to 
activate the STAT3 signaling pathway) and EGF (known to activate the ERK signaling 
pathway) is unknown. In this study, we unveil a signaling pathway that is initiated by 
endothelial cells and that results in the activation of STAT3, Akt, and ERK in HNSCC 
cells. Notably, blockade of endothelial cell-initiated signaling had a direct impact on 
tumor cell survival and migration.  
 
Materials and Methods 
 
Cell Culture 
Oral squamous cell carcinoma (OSCC3, gift of M. Lingen, University of 
Chicago), University of Michigan-squamous cell carcinoma (UM-SCC-1, UM-SCC-17B, 
and UM-SCC-74A, gift of T. Carey, University of Michigan) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin 
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(Invitrogen). Primary human dermal microvascular endothelial cells (HDMEC; Cambrex, 
Walkersville, MD) were cultured in endothelial growth medium-2 (EGM2-MV; 
Cambrex). Pools of HDMEC stably transduced with Bcl-2 (HDMEC-Bcl-2) and 
HDMEC-LXSN (empty vector controls) were generated with retroviruses and cultured in 
EGM2-MV supplemented with 250 µg/ml G418 (Cellgro, Mediatech Inc., Herndon, VA), 
as described (Nor et al., 1999; Nor et al., 2001a). Conditioned medium (CM) from 
HDMEC was prepared in endothelial cell medium (EBM) without supplementation with 
growth factors or serum from 24-hour cultures. 
 
Non-contact co-culture assays 
2 x 105 tumor cells (OSCC3, UM-SCC-17B, UM-SCC-1, or UM-SCC-74A) were 
plated in 1 μm-pore cell culture inserts containing PET (polyethylene terephthalate) 
track-etched membranes (Becton Dickinson, Franklin Lakes, NJ) in 6-well plates 
(Multiwell; Becton Dickinson). HDMEC (1 x 105) were cultured in the bottom wells of 
the Transwell system. Serum-free endothelial basal medium (EBM) or EGM2-MV was 
used for these co-culture experiments. Total RNA and protein from both endothelial and 
tumor cells was collected 24 hours after cells were combined, and microarrays or western 
blots were performed. 
 
Stable short hairpin RNA (shRNA) transduction 
Lentiviruses expressing a short hairpin RNA (shRNA) construct for silencing IL-
6, CXCL8, or EGF (Vector Core, University of Michigan) were generated in human 
embryonic kidney cells (293T) transfected by the calcium phosphate method, as 
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described (Kaneko et al., 2007). A scrambled oligonucleotide sequence (shRNA-C) was 
used as control. Supernatants were collected 48 hours after transfection and used to infect 
HDMEC in 1:1 dilution medium containing 4 µg/ml polybrene (Sigma-Aldrich, St. Louis, 
MO). Cells were selected and maintained in EGM2-MV supplemented with 1 µg/ml 
puromycin (InvivoGen, San Diego, CA). Downregulation of IL-6, CXCL8, or EGF 
expression was confirmed by ELISA.  
 
Western blots 
8 x 105 OSCC3, UM-SCC-1, UM-SCC-17B, or UM-SCC-74A were plated in 60 
mm dishes, starved overnight, and exposed to HDMEC conditioned medium (CM) or 
EBM for the indicated time points. Alternatively, tumor cells were exposed to HDMEC 
CM containing 0.1-2 µg/ml anti-IL-6, anti-CXCL8, anti-EGF, or IgG isotype control (R 
& D Systems); or CM collected from HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, 
HDMEC-shRNA-EGF, or HDMEC-shRNA-C. Tumor cells were also exposed to 1-50 
ng/ml rhIL-6 (Biosource, Camarillo, CA), 1-100 ng/ml rhCXCL8, or 1-100 rhEGF (R & 
D Systems, Minneapolis, MN) for 30 minutes. Signaling pathways were blocked by pre-
incubating tumor cells for 1 to 2 hours with 0.5-20 µM Stattic (STAT3 inhibitor V, 
Calbiochem, San Diego, CA), 5-100 µM LY294002 (PI3 kinase inhibitor, Cell Signaling 
Technology, Danvers, MA), or 5-100 µM U0126 (MEK1/2 inhibitor, Cell Signaling), and 
exposed to HDMEC CM. Protein (30 µg) was electrophoresed on SDS-polyacrylamide 
gels and transferred to nitrocellulose membranes. Primary antibodies were: mouse anti-
human phospho-STAT3, rabbit anti-human STAT3, rabbit anti-human phospho-Akt, 
rabbit anti-human Akt, rabbit anti-human phospho-ERK1/2, mouse anti-human ERK1/2 
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(Cell Signaling); rabbit anti-human VEGFR1, rabbit anti-human IL-6R, rabbit anti-
human EGFR (Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-human gp130 
(Biosource, Camarillo, CA); mouse anti-human CXCR1, rabbit anti-human CXCR2 
(Abcam, Cambridge, MA); hamster anti-human Bcl-2 (BD Biosciences, San Jose, CA); 
mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon, Millipore,  
Billerca, MA). Immunoreactive proteins were visualized by SuperSignal West Pico 
chemiluminescent substrate (Thermo Scientific, Rockford, IL). 
 
GEArray RNA Microarrays 
Gene expression of tumor cells (OSCC3, UM-SCC-17B, UM-SCC-1A, or UM-
SCC-74A) co-cultured with HDMEC was compared with tumor cells cultured alone 
using GEArray Q serties (SuperArray Bioscience Corporation, Frederick, MD). RNA 
was purified using the RNeasy kit (Qiagen, Valencia, CA) and 3 µg total RNA was 
analyzed using Human Signaling Transduction in Cancer and Human Angiogenesis gene 
arrays, according to the manufacturer’s instructions. 
 
Affymetrix Microarray 
Total RNA was isolated from HDMEC cultured alone or co-cultured with OSCC3 
using Trizol (Invitrogen, Carlsbad, CA). The RNA was purified using the RNeasy kit 
(Qiagen, Valencia, CA) and 10 µg total RNA was used to perform microarray analysis on 
Human Genome U133 Plus 2.0 (Affymetrix, Santa Clara, CA). Briefly, cDNA was 
synthesized from total RNA (One-Cycle cDNA Synthesis Kit, Affymetrix) and in vitro 
transcription was followed to make biotin labeled cRNA (IVT Labeling Kit, Affymetrix). 
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Fragmented cRNA was hybridized with microarray. After microarray washing, staining, 
and scanning, data was collected and further analyzed using Data Mining software and 
NetAffx Analysis Center (Affymetrix). 
 
Enzyme-linked immunosorbent assay (ELISA) 
Supernatants of 24-hour endothelial or tumor cell cultures were collected and 
centrifuged to eliminate debris. IL-6, CXCL8, and EGF expression was determined using 
ELISA kits (Quantikine; R & D Systems, Minneapolis, MN) according to the 
manufacturer’s instructions. Data were normalized by cell number. 
 
Sulforhodamine B Cell Proliferation Assays 
OSCC3 (2 x 103) were seeded in 96-well plates (Becton Dickinson) and exposed 
to EBM, HDMEC conditioned medium (CM) containing 1 µg/ml anti-IL-6, anti-CXCL8, 
anti-EGF neutralizing antibodies, or IgG isotype control. Alternatively, tumor cells were 
exposed to CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-
shRNA-EGF, or HDMEC-shRNA-C. Tumor cells were also exposed to HDMEC CM 
containing 5 µM Stattic (Calbiochem), 10 µM LY294002, 10 µM U0126 (Cell 
Signaling), or DMSO vehicle control. After 24, 48, or 72 hours, cells were fixed with 
10% trichloracetic acid and stained with 0.4% sulforhodamine B (SRB) solution as 
previously described (Zeitlin et al., 2006). Plates were read in a microplate reader at 565 




HDMEC conditioned medium (CM) was pre-incubated with 1 µg/ml anti-IL-6, 
anti-CXCL8, anti-EGF, or IgG control (R & D Systems) for 1 hour, and 400 µl of CM 
was added to 24-well companion plates (Fisher Scientific, Pittsburgh, PA). Alternatively, 
CM collected from HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-
EGF, or HDMEC-shRNA-C was used. OSCC3 (2 x 105) were serum-starved overnight, 
loaded onto 8 µm pore-sized cell culture inserts (Becton Dickinson), and allowed to 
migrate for 24 hours towards HDMEC CM.  In addition, OSCC3 were pre-incubated for 
1 to 2 hours with 5 µM Stattic (Calbiochem), 10 µM LY294002, 10 µM U0126 (Cell 
Signaling), or DMSO vehicle control. Unconditioned EBM was used as negative control. 
Migrated cells were trypsinized, collected, and stained with 2 µM Cell Tracker Green 
(Invitrogen) for 1 hour. Fluorescence was read at 485/535 nm in a microplate reader 
(Tecan, Salzburg, Austria). 
 
Survival Assays 
OSCC3 (3 X 105) were seeded in 6-well ultra-low attachment plates (Corning 
Incorporated, Corning, NY) using EBM, HDMEC conditioned medium (CM) containing 
1 µg/ml anti-IL-6, anti-CXCL8, anti-EGF, or IgG control (R & D Systems); CM from 
HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-
shRNA-C; or HDMEC CM containing 5 µM Stattic (Calbiochem), 10 µM LY294002, 10 
µM U0126 (Cell Signaling), or DMSO vehicle control. OSCC3 seeded in regular 6-well 
plates (Becton Dickinson) were used as positive control. After 24 hours, propidium 
iodide staining followed by flow cytometry was used to determine the percentage of dead 
cells, as described (Nor et al., 2002).  In addition, percentage of apoptotic cells was 
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determined by Trypan blue (Gibco, Invitrogen Corporation, Grand Island, NY) exclusion 
method after 24 to 48 hours. 
 
Statistical analyses  
T-tests or one-way analysis of variance was performed using the SigmaStat 2.0 




Endothelial cell-secreted factors induce phosphorylation of STAT3, Akt, and ERK 
in head and neck squamous cell carcinoma cells 
The overall hypothesis underlying this study is that endothelial cell-secreted 
factors initiate signaling pathways in tumor. To begin to address this hypothesis, we 
exposed a panel of head and neck tumor cells, i.e. OSCC3 (Figure 2.1A), UM-SCC-17B 
(Figure 2.1B), UM-SCC-1 (Figure 2.1C), or UM-SCC-74A (Figure 2.1D) to serum-free 
endothelial cell (HDMEC) conditioned medium (CM) and analyzed the phosphorylation 
levels of key signaling molecules over time. We observed that STAT3, Akt, and ERK 
were consistently phosphorylated in the tumor cells upon exposure to endothelial cell 
CM, as compared to tumor cells treated with unconditioned medium (Figure 2.1). The 
induction of phosphorylation by endothelial cell CM was observed primarily between 15 
minutes and 1 hour, decreasing after 4 to 24 hours as expected. The four tumor cell lines 
that we tested showed different phosphorylation levels upon exposure to HDMEC CM, 
but the trends among the cell lines were similar. To verify the results of the CM 
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experiments with a second experimental model, we used a non-contact co-culture system 
with HDMEC and HNSCC cells. Within one hour, STAT3, Akt, and ERK 
phosphorylation was enhanced in OSCC3 co-cultured with HDMEC, as compared to 
OSCC3 in single culture (Figure 2.2A). Notably, even after 24 hours in co-culture the 
phosphorylation status of STAT3 was still upregulated in two (out of four) HNSCC cell 
lines tested here (Figure 2.2B). Collectively, these results showed that endothelial cell-
secreted factors induce STAT3, Akt, and ERK phosphorylation in HNSCC cells. 
 
IL-6, CXCL8, and EGF are upregulated in endothelial cells co-cultured with head 
and neck squamous cell carcinoma cells 
 In search for putative factors secreted by endothelial cells that could lead to 
STAT3, Akt, and ERK phosphorylation, we performed an Affymetrix microarray 
comparing the gene expression profile of HDMEC cultured alone with HDMEC co-
cultured with OSCC3. We observed that IL-6, CXCL8, and EGF were upregulated in 
HDMEC when co-cultured with OSCC3 (Figure 2.3A). We then analyzed whether the 
tumor cells express the receptors for IL-6, CXCL8, and EGF. All tumor cells tested here 
express IL-6R and gp130 (receptors for IL-6); CXCR1 and CXCR2 (receptors for 
CXCL8); and EGFR (receptor for EGF) (Figure 2.3B). We selected OSCC3 cells for 
most of the remaining experiments presented here, and used a second HNSCC cell line to 
verify reproducibility of results of key experiments. Next, we compared the expression 
levels of IL-6, CXCL8, and EGF in endothelial and tumor cells. Since it is known that 
HNSCC cells secret high levels of VEGF (Eisma et al., 1997), we exposed HDMEC to 
VEGF and evaluated the impact of this treatment on the expression of IL-6, CXCL8, and 
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EGF. Notably, the expression of IL-6 and CXCL8, but not EGF, was upregulated in 
endothelial cells treated with VEGF (Figure 2.3C). We observed that IL-6 induced 
phosphorylation of STAT3, CXCL8 enhanced phosphorylation of Akt and ERK 
compared with untreated group (first lane), and EGF enhanced phosphorylation of 
STAT3, Akt, and ERK (Figure 2.3D). We also exposed OSCC3 to the combination of IL-
6, CXCL8, and EGF and observed similar signaling trends as compared to CM treatment 
(Figure 2.3E) 
 
Effect of endothelial cell-secreted IL-6, CXCL8, and EGF on the phosphorylation of 
STAT3, Akt, and ERK in head and neck squamous cell carcinoma cells 
To evaluate the role of these cytokines on endothelial cell-initiated signaling 
pathways in tumor cells, we exposed OSCC3 to HDMEC CM in the presence of 
neutralizing antibodies to IL-6, CXCL8, or EGF, and analyzed phosphorylation of 
STAT3, Akt, and ERK. Blockade of IL-6 in HDMEC CM blocked STAT3 
phosphorylation in OSCC3 but had no effect on the phosphorylation levels of Akt and 
ERK, as compared with IgG controls (Figure 2.4A). Blockade of CXCL8 in HDMEC 
CM slightly decreased phosphorylation levels of STAT3 and Akt, but had no significant 
effect on ERK (Figure 2.4A). Finally, blockade of EGF in HDMEC CM eliminated ERK 
phosphorylation in OSCC3 compared with IgG control, while had no effect on STAT3 
and Akt phosphorylation levels (Figure 2.4A). To evaluate specifically the role of 
endothelial cell initiated events, we silenced expression of IL-6, CXCL8, or EGF in 
HDMEC. The effectiveness of the downregulation was verified by ELISA (Figure 2.4B). 
OSCC3 were then exposed to CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-
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CXCL8, HDMEC-shRNA-EGF, or control HDMEC-shRNA-C. Downregulation of IL-6 
and EGF in endothelial cells resulted in inhibition of phosphorylation of STAT3 and 
ERK in tumor cells, respectively (Figure 2.4C). However, downregulation of CXCL8 in 
endothelial cells did not result in an observable inhibition of Akt in the tumor cells, 
presumably because HDMEC-shRNA-CXCL8 cells still secreted substantial amounts of 
this protein.  
 
Bcl-2 signaling induces IL-6, CXCL8, and EGF expression in endothelial cells 
To begin to understand the mechanisms involved in the upregulation of IL-6, 
CXCL8, and EGF in the endothelial cells, we evaluated a potential role for Bcl-2 
signaling. Previous work has shown that tumor cell-secreted VEGF induces Bcl-2 
expression in endothelial cells, and that upregulation of Bcl-2 in microvascular 
endothelial cells is sufficient to enhance tumor progression (Nor et al., 1999; Nor et al., 
2001a). Notably, Bcl-2 is significantly upregulated in the endothelial cells of head and 
neck tumor microvessels (Kaneko et al., 2007). We have also shown that Bcl-2 
upregulates CXCL1 and CXCL8 expression in endothelial cells through the IKK/I-
kB/NF-kB pathway (Karl et al., 2005), and it is known that NF-kB directly stimulates the 
transcription of several cytokines and growth factors (Karin et al., 2002). These 
observations led to the hypothesis that Bcl-2 induces expression of IL-6 and EGF in 
endothelial cells. To test this hypothesis, we generated pools of endothelial cells 
overexpressing Bcl-2 (HDMEC-Bcl-2) and empty vector controls (HDMEC-LXSN) 
(Figure 2.5A). HDMEC-Bcl-2 secreted significantly higher levels of IL-6, CXCL8, and 
EGF than HDMEC-LXSN (Figure 2.5B). Next, we analyzed phosphorylation levels of 
 60
STAT3, Akt, and ERK in OSCC3 when exposed to CM collected from HDMEC-LXSN 
and HDMEC-Bcl-2. At initial time points (i.e. 15 minutes) the phosphorylation levels 
induced by HDMEC-LXSN and HDMEC-Bcl-2 CM were similar (Figure 2.5C). 
However, at later time points, phosphorylation of STAT3 (4 and 24 hours) and ERK (4 
hours) was higher when OSCC3 cells were exposed to HDMEC-Bcl-2 CM than in 
OSCC3 exposed to HDMEC-LXSN CM (Figure 2.5C). Collectively, these results 
showed that Bcl-2 signaling induces expression of IL-6, CXCL8, and EGF in endothelial 
cells. Moreover, Bcl-2 expression levels in the endothelial cells had a significant impact 
on the phosphorylation status of STAT3 and ERK, but not Akt, in the tumor cells. 
 
Endothelial cell-secreted factors enhance the motility and prevent anoikis of head 
and neck squamous cell carcinoma cells 
To understand the biological impact of endothelial cell-induced tumor cell 
STAT3, Akt, and ERK phosphorylation, we exposed the OSCC3 to HDMEC CM 
containing inhibitors of these pathways and evaluated tumor cell proliferation, survival, 
and migration. We used increasing concentrations of Stattic (STAT3 inhibitor), 
LY294002 (PI3K/Akt inhibitor), or U0126 (MEK/ERK inhibitor) (Figure 2.6A), and 
selected the lowest dose able to inhibit activation of STAT3, Akt, and ERK to carry out 
these experiments. Viability experiments showed that these dosages were not cytotoxic 
(data not shown). No difference was observed in HNSCC proliferation when cells were 
exposed to HDMEC CM for up to 72 hours, as compared to exposure to unconditioned 
medium. Blockade of IL-6, CXCL8, or EGF in the CM using neutralizing antibodies 
(Figure 2.7A) or shRNA in HDMEC (Figure 2.7B) did not affect HNSCC proliferation. 
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As expected, direct blockade of STAT3, Akt, or ERK pathways with chemical inhibitors 
decreased tumor cell proliferation (Figure 2.7C). Notably, HDMEC CM had a significant 
effect on tumor cell survival. To analyze the effect of endothelial cell derived factors on 
tumor cell survival we cultured OSCC3 cells in extra low attachment plates. The 
percentage of dead cells was analyzed by flow cytometry (Figure 2.6) or by cell counting 
(Figure 2.8). The number of dead cells was significantly higher in low attachment plates 
in EBM compared to normal cell culture plates (Figure 2.6B; Figure 2.8). CM from 
HDMEC protected OSCC3 from anoikis induced by preventing the attachment of the 
tumor cells to the plate (Figure 2.6B; Figure 2.8). Notably, blockade of IL-6, CXCL8, 
and EGF in the CM using neutralizing antibodies (Figure 2.6B, a; Figure 2.8A, a-b) or 
gene silencing in HDMEC (Figure 2.6B, b; Figure 2.8B, a-b) inhibited the protective 
effect mediated by endothelial cells. Blockade of STAT3, Akt, or ERK activity with 
Stattic, LY294002, or U0126 showed similar results (Figure 2.6B, c; Figure 2.8C, a-b). 
To evaluate the effect of endothelial cell-secreted IL-6, CXCL8, or EGF on tumor cell 
migration we also used two experimental strategies. Blockade of IL-6, CXCL8, or EGF 
with neutralizing antibodies (Figure 2.6C, a), or shRNA in HDMEC (Figure 2.6C, b) 
inhibited migration of OSCC3, as compared to controls. In addition, blockade of STAT3, 
Akt, or ERK using Stattic, LY294002, or U0126 also inhibited OSCC3 migration (Figure 
2.6C, c). Collectively, these data demonstrate that endothelial cell-initiated signaling has 
a significant impact on tumor cell survival and migration, two critical elements of the 





 This study suggests a new paradigm for endothelial cell and tumor cell 
interactions in the tumor microenvironment. We demonstrate here that endothelial cells 
play an active role in establishing tumor cell phenotypes that are critical for the 
pathobiology of cancers, namely, tumor cell survival and migration. Several reports 
suggest a role for inflammation, extracellular matrix, macrophages, and stromal 
fibroblasts in the initiation and progression of carcinomas (Bhowmick and Moses, 2005; 
Coussens and Werb, 2002; Halin et al., 2009). However, the role of endothelial cells in 
activating oncogenic signaling pathways in tumor cells is just starting to be unveiled. 
Notably, the current paradigm is that tumor cell-initiated signaling are the predominant. 
Yet, this study provides evidence for endothelial cells as key players in the determination 
of the tumor cell phenotype. 
We observed that endothelial cell-initiated signals activate three key intracellular 
signaling molecules, namely STAT3, Akt, and ERK in HNSCC. The role of these 
pathways in cancer has been extensively studied. STAT3 is activated in a wide variety of 
cancers including HNSCC. Notably, studies have consistently demonstrated an essential 
role for STAT3 in tumor progression (Buettner et al., 2002; Masuda et al., 2007; 
Nikitakis et al., 2004). The Akt signaling network is considered a key determinant of the 
biological aggressiveness of tumors. PI3K/Akt is often activated in HNSCC (Fenic et al., 
2007; Opel et al., 2007). And finally, ERK is one of the most important signaling 
molecules in the regulating cell proliferation and is overexpressed in a variety of tumors, 
including HNSCC (Mishima et al., 2002). The results of our study suggest that 
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endothelial cells play an active role in the activation of these pathways in HNSCC. Our 
results demonstrated that STAT3, Akt, and ERK were phosphorylated in tumor cells 
without requiring cell contact. These results suggested that endothelial cell-secreted 
factors were able to activate these signaling pathways in the tumor cells. This is in line 
with observations from other research groups that have characterized soluble factors as 
key regulators of tumorigenesis (Balkwill, 2004; van der Horst et al., 2008; Vicari and 
Caux, 2002). One of the challenges of our study was to find out which factors were 
mediating these effects in the tumor cells. Affymetrix microarrays revealed several genes 
upregulated in endothelial cells when co-cultured with tumor cells. Several validation 
experiments, together with the existing knowledge of the effects of IL-6, CXCL8, and 
EGF on STAT3, Akt, and ERK signaling, led us to focus on these three soluble 
mediators. Although previous studies have already shown that endothelial cells 
overexpressing Bcl-2 secrete high levels CXCL8 (Karl et al., 2005), the role of 
endothelial cell-secreted IL-6, CXCL8, and EGF on activation of signaling pathways in 
tumor cells have not been described. IL-6 is a cytokine that affects a variety of biological 
functions including immune response, inflammation, hematopoiesis, and oncogenesis by 
regulating cell growth, survival, and differentiation (Hirano et al., 2000; Van Snick, 
1990). IL-6 is one of the major activators of STAT3 signaling (Hirano et al., 2000; Hodge 
et al., 2005; Huang, 2007), although it can also stimulate PI3K/Akt and ERK pathways 
(Kamimura et al., 2003). Recent studies correlate IL-6 levels in HNSCC patients with 
poor prognosis (Duffy et al., 2008; Heimdal et al., 2008; Squarize et al., 2006). CXCL8 is 
a member of CXC chemokine family that contributes to cancer progression through 
several mechanisms, including the promotion of angiogenesis (Koch et al., 1992; Strieter 
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et al., 1995). Many cancer cells constitutively secrete CXCL8 and its receptors CXCR1 
and CXCR2, and it has been established that CXCL8 is an autocrine growth factor for a 
variety of human cancer cells (Zhu and Woll, 2005). CXCL8 can also activate STAT3, 
PI3K/Akt, and ERK signaling pathways (Burger et al., 2005; Fuhler et al., 2005). 
Overexpression of EGFR has been reported in the majority of HNSCC cases (Grandis and 
Tweardy, 1993; Grandis et al., 1998). Notably, downstream intracellular targets of EGFR 
include STAT3, PI3K/Akt, and ERK pathways (Kijima et al., 2002; Squarize et al., 2006; 
Sriuranpong et al., 2003). One concludes from these studies that each one of these three 
cytokines has effects that may converge towards these three pathways in tumor cells. 
However, under our experimental conditions we observed that the primary effect of 
endothelial cell-derived IL-6 was the activation of STAT3, the primary effect of CXCL8 
was on the activity of Akt, and the primary effect of EGF was on ERK activity in 
HNSCC.  
Previous work has shown that Bcl-2 expression levels in endothelial cells have a 
direct effect on tumor growth (Kaneko et al., 2007; Nor et al., 2001a). Here, we 
demonstrate that IL-6 and EGF are upregulated in endothelial cells overexpressing Bcl-2, 
and that CM from these cells further enhanced phosphorylation of STAT3 and ERK, two 
pathways implicated in the survival of tumor cells. Notably, it has been previously 
demonstrated that the apoptotic index of tumors vascularized with endothelial cells 
overexpressing Bcl-2 was lower than the index in tumors vascularized with control 
endothelial cells (Nor et al., 2001a). At that time, the data were interpreted as simply an 
increase in endothelial cell survival and tumor microvessel density directly due to the 
upregulation of Bcl-2 expression in these cells. However, the data presented here suggest 
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that the activation of major survival pathways for SCC mediated by endothelial cell-
secreted factors may also have contributed to those results.  
It was critical to us to understand the biological significance of endothelial cell-
induced activation of the STAT3/Akt/ERK pathways in squamous cell carcinomas. 
Surprisingly, we did not observe a significant effect in tumor cell proliferation when we 
blocked endothelial cell derived IL-6, CXCL8, or EGF. We attributed these negative 
results to the exceedingly high proliferation rate of OSCC3. We reasoned that these cells 
have such a high basal mitotic activity that blockade of one additional mitogenic pathway 
derived from the endothelial cells is not sufficient to cause a significant change in 
OSCC3 cell numbers. On the other hand, we observed that endothelial cell secreted 
factors significantly protected the tumor cells from anoikis. Notably, this protective effect 
was partially inhibited when we downregulated IL-6, CXCL8, or EGF in the endothelial 
cells. And finally, considering that IL-6, CXCL8, and EGF have been characterized as 
chemotactic factors, we studied their effect on tumor cell motility using migration assays. 
These experiments demonstrated that endothelial cells are capable of generating a 
chemotactic gradient that induces tumor cell motility towards the blood vessels. Such 
findings may help us to understand the mechanisms underlying the process of field 
cancerization, which involves the lateral spread of malignant disease and is commonly 
observed in patients with head and neck cancer (Ha and Califano, 2003; Warner et al., 
2008). We hypothesize that endothelial cells play a key role in field cancerization by 
providing chemotactic signals that enhance the invasive phenotype of tumor cells, and by 
activating survival signals that protect the tumor cells against anoikis once these cells are 
displaced from their original microenvironment.  
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Collectively, these data led to a new model for crosstalk between endothelial and 
SCC cells. It is known that tumor cell-secreted VEGF binds to its cognate receptors in 
endothelial cells and induce expression of Bcl-2 (Kaneko et al., 2007; Nor et al., 1999). 
Bcl-2 enhances IL-6, CXCL8, and EGF synthesis and secretion by endothelial cells. The 
endothelial cell-secreted factors induce activation of the STAT3, Akt, and ERK signaling 
pathways in tumor cells. The biological outcome of this crosstalk is a significant increase 
in tumor cell survival and migration. We postulate that better understanding of the 
complexity of signal transduction processes between tumor cells and other cells from the 
tumor microenvironment may help to optimize the overall therapeutic benefit of 
molecularly targeted drugs. The fact that tumor-associated endothelial cells are readily 
accessible to drugs injected in the circulation makes them a particularly attractive 
therapeutic target. The work presented here demonstrated that blockade of specific 
pathways in endothelial cells may have a direct impact on tumor cell survival and 
migration, two critical components of the pathobiology of squamous cell carcinomas.  
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Figure 2.1. Endothelial cell–derived soluble factors activate STAT3, Akt, and ERK 
pathways in tumor cells. (A) OSCC3; (B) UM-SCC-17B; (C) UM-SCC-1; or (D) UM-
SCC-74A were serum-starved overnight and exposed to HDMEC conditioned medium 
(CM) or control unconditioned medium (EBM) for the indicated time points. 




Figure 2.2. Tumor cells co-cultured with endothelial cells show higher 
phosphorylation of STAT3, Akt, and ERK compared to tumor cells cultured alone. 
(A) Western Blot for phosphorylated and total STAT3, Akt, and ERK in OSCC3 cultured 
alone or co-cultured with HDMEC for 1 hour. (B) Western Blot for phosphorylated and 
total STAT3 in OSCC3, UM-SCC-17B, UM-SCC-1, or UM-SCC-74A cultured alone or 





Figure 2.3. Endothelial cells show upregulated IL-6, CXCL8, and EGF expression 
when co-cultured with tumor cells. (A) Genome wide mRNA expression analysis was 
performed in HDMEC co-cultured with OSCC3, using HDMEC cultured alone (single 
culture) as controls. Black bars represent the fold-increase of IL-6, CXCL8, and EGF 
expression in HDMEC co-cultured with OSCC3 compared with HDMEC cultured alone 
(gray bars). (B) Western Blot for IL-6R, gp130, CXCR1, CXCR2, EGFR, and VEGFR2 
expression in HDMEC, OSCC3, UM-SCC-17B, UM-SCC-1A, and UM-SCC-74A. (C) 
ELISA for IL-6, CXCL8, and EGF expression in HDMEC, OSCC3, or HDMEC exposed 
to 50 ng/ml VEGF165. Asterisk depicts significant difference (p<0.001), as compared to 
HDMEC. (D) Western Blot for phosphorylated and total STAT3, Akt, and ERK in 
OSCC3 serum-starved overnight and exposed to 1-50 ng/ml rhIL-6, 1-100 ng/ml 
rhCXCL8, or 1-100 ng/ml rhEGF for 30 minutes. (E) Western Blot for phosphorylated 
and total STAT3, Akt, and ERK in OSCC3 serum-starved overnight and exposed for 30 
minutes to 20 ng/ml rhIL-6, 50 ng/ml rhCXCL8, 50 ng/ml rhEGF, or the combination of 




Figure 2.4. Effect of endothelial cell-secreted IL-6, CXCL8, and EGF on the 
phosphorylation of STAT3, Akt, and ERK in HNSCC cells. (A) Western Blot for 
phosphorylated and total STAT3, Akt, and ERK in OSCC3 serum-starved overnight and 
exposed to EBM; HDMEC conditioned medium (CM) containing 0-2 µg/ml anti-IL-6, 
anti-EGF, anti-CXCL8 neutralizing antibodies; or IgG control for 30 minutes. (B) ELISA 
for IL-6, CXCL8, or EGF expression in HDMEC transfected with shRNA-control 
(shRNA-C), shRNA-IL-6, shRNA-CXCL8, or shRNA-EGF. Asterisk depicts significant 
difference (p<0.001), as compared to shRNA-C. (C) Western Blot for phosphorylated and 
total STAT3, Akt, and ERK in OSCC3 serum-starved overnight and exposed to EBM, or 
to CM from HDMEC-shRNA-C, HDMEC-shRNA-IL-6, HDMEC-shRNA-CXCL8, or 





Figure 2.5. Bcl-2 induces IL-6, CXCL8, and EGF expression in endothelial cells. (A) 
Pools of endothelial cells overexpressing Bcl-2 (HDMEC-Bcl-2) were generated using 
retroviral vectors. Transgene expression was examined by Western Blot from HDMEC-
LXSN (empty vector control) and HDMEC-Bcl-2. (B) ELISA for IL-6, CXCL8, or EGF 
expression in HDMEC-LXSN or HDMEC-Bcl-2. Asterisk depicts significant difference 
(p<0.001), as compared to control HDMEC-LXSN. (C) OSCC3 were serum-starved 
overnight and exposed to EBM, conditioned medium (CM) from HDMEC-LXSN, or 
from HDMEC-Bcl-2 at indicated time points. Western Blots were used to determine 




Figure 2.6. Endothelial cell-secreted IL-6, CXCL8, and EGF enhance tumor cell 
survival and migration via STAT3, Akt, and ERK pathways. (A) To optimize the 
dose of STAT3, Akt, and ERK inhibitors, OSCC3 were serum-starved overnight, pre-
incubated for 1-2 hours with (a) 0-20 µM Stattic, (b) 0-100 µM LY294002, or (c) 0-100 
µM U0126, and exposed to EBM or HDMEC conditioned medium (CM) for 30 minutes. 
Inhibition of STAT3, Akt, and ERK phosphorylation was determined by Western Blot. 
(B) To evaluate tumor cell survival, OSCC3 were maintained in low attachment plates 
(LAP) for 24 hours in EBM, (a) CM HDMEC containing 1 µg/ml anti-IL-6, anti-CXCL8, 
anti-EGF neutralizing antibodies, or IgG control; (b) CM from HDMEC-shRNA-IL-6, 
HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C; or (c) CM 
HDMEC containing 5 µM Stattic, 10 µM LY294002, 10 µM U0126, or DMSO vehicle 
control. OSCC3 cultured in regular plates (NP) with EBM were used as controls. (C) To 
evaluate tumor cell migration, OSCC3 were serum-starved overnight and allowed to 
migrate for 24 hours towards EBM, (a) HDMEC CM containing 1 µg/ml anti-IL-6, anti-
CXCL8, anti-EGF, or IgG control; (b) CM from HDMEC-shRNA-IL-6, HDMEC-
shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C; or (c) HDMEC CM 
containing 5 µM Stattic, 10 µM LY294002, 10 µM U0126, or DMSO vehicle control. 
Data presented here were normalized by control groups. Asterisk depicts significant 






Figure 2.7. Endothelial cell-secreted IL-6, CXCL8, and EGF do not affect tumor cell 
proliferation. OSCC3 were exposed for 24 (a), 48 (b), or 72 (c) hours to EBM, (A) 
HDMEC conditioned medium (CM) containing 1 µg/ml anti-IL-6, anti-CXCL8, anti-
EGF neutralizing antibodies, or IgG control; (B) CM from HDMEC-shRNA-IL-6, 
HDMEC-shRNA-CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C; or (C) 
HDMEC CM containing 5 µM Stattic, 10 µM LY294002, 10 µM U0126, or DMSO 
vehicle control. Notably, direct inhibition of STAT3, Akt or ERK with chemical 
inhibitors slowed down tumor cell proliferation, as determined by SRB assays. Asterisk 




Figure 2.8. Endothelial cell-secreted IL-6, CXCL8, and EGF enhance tumor cell 
survival via STAT3, Akt, and ERK pathways. To evaluate tumor cell survival, OSCC3 
were maintained in low attachment plates (LAP) for 24 hours (a) or 48 hours (b) in EBM, 
(A) CM HDMEC containing 1 µg/ml anti-IL-6, anti-CXCL8, anti-EGF neutralizing 
antibodies, or IgG control; (B) CM from HDMEC-shRNA-IL-6, HDMEC-shRNA-
CXCL8, HDMEC-shRNA-EGF, or HDMEC-shRNA-C; or (C), CM HDMEC containing 
5 µM Stattic, 10 µM LY294002, 10 µM U0126, or DMSO vehicle control. OSCC3 
cultured in regular plates (NP) with EBM were used as controls. Percentage of dead cells 
was determined by the trypan blue exclusion method. Asterisk depicts significant 
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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer worldwide, with more than 500,000 new cases annually. Despite improvement in 
treatment strategies, the 50% five-year survival rate has not improved significantly over 
the past 30 years. The finding of novel molecular therapeutic targets may improve the 
treatment of HNSCC patients. Targeting endothelial cells rather than cancer cells is an 
attractive approach for cancer therapy, since the vascular endothelium is directly 
accessible to systemic drugs and less likely to acquire drug resistance. We have 
previously shown that endothelial cell-secreted factors activate STAT3, Akt, and ERK 
signaling pathways HNSCC cells. Here, we demonstrated that HNSCC cells adjacent to 
blood vessels showed increased phosphorylation of STAT3, Akt, and ERK in xenograft 
human tumors. Inhibition of endothelial cell-induced Akt signaling in HNSCC cells 
increased ERK phosphorylation, and inhibition of ERK pathway increased Akt 
activation, whereas STAT3 phosphorylation levels were not changed by blockade of 
endothelial cell-induced Akt or ERK pathways. Among these three pathways, STAT3 
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presented the higher phosphorylation levels, which is mainly induced by endothelial cell-
secreted IL-6. Notably, downregulation of IL-6 in tumor-associated endothelial cells by 
shRNA inhibited the growth of xenograft human tumors and decreased intratumoral 
microvessel density. These results suggest that targeted inhibition of IL-6 secreted by 




Head and neck squamous cell carcinoma (HNSCC) includes malignant lesions 
arising in the oral cavity, larynx, and pharynx, and represents the sixth most common 
cancer worldwide, with more than half a million new cases annually (Jemal et al., 2008; 
Parkin et al., 2005). Despite improvement in treatment strategies involving surgery, 
radiation therapy, and chemotherapy, the prognosis of HNSCC patients with advanced 
stage of disease remains largely unsatisfactory as a consequence of loco-regional 
recurrence (Pignon et al., 2007; Scully and Bagan, 2008). The five-year survival rate after 
diagnosis of HNSCC is approximately 50%, and has not improved significantly over the 
past 30 years (Mao et al., 2004; Parkin et al., 2005). HNSCC development and 
progression involves the accumulation of genetic and epigenetic alterations, and the 
aberrant expression and/or function of regulators of cell signaling, growth, survival, 
motility, cell cycle, and angiogenesis (Forastiere et al., 2001; Haddad and Shin, 2008). 
The deregulation of signaling cascades including the transcription factor signal transducer 
and activator transcription 3 (STAT3), the phosphatidylinositol-3-kinase (PI3K)/Akt, and 
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the mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 
pathways are implicated in the pathogenesis of HNSCC (Molinolo et al., 2009).  
The recent development of molecular targeted therapies may lead to the rational 
selection of treatment modalities for HNSCC patients based on specific molecular 
mechanisms whose deregulated activity contributes to the initiation, development, and 
metastatic spread (Dietz et al., 2008; Glazer et al., 2009; Langer, 2008; Matta and Ralhan, 
2009; Shirai and O'Brien, 2007). Several studies describe the targeted inhibition of 
signaling pathways, such as STAT3 (Aggarwal et al., 2006; Boehm et al., 2008; Fletcher 
et al., 2008; Grandis et al., 1998; Leeman et al., 2006), PI3K/Akt (Amornphimoltham et 
al., 2004; Moral and Paramio, 2008), and MAPK/ERK (Friday and Adjei, 2008; Roberts 
and Der, 2007) as potential therapeutic approaches for HNSCC. We have recently 
reported that factors secreted by primary human dermal microvascular endothelial cells 
(HDMEC) namely IL-6, CXCL8, and EGF activate STAT3, Akt, or ERK pathways in 
HNSCC (Neiva et al., 2009). We have also shown that inhibition of endothelial cell-
secreted IL-6, CXCL8, and EGF decreases STAT3, Akt, and ERK phosphorylation 
respectively, and reduces tumor cell survival and migration in vitro (Neiva et al., 2009). 
However, we do not know whether downregulation of endothelial cell-secreted factors 
affects the activity of these signaling pathways in vivo, and whether endothelial cell-
initiated signaling contributes to tumor growth.  
 The search for anticancer therapeutic agents that target tumor cells specifically 
and selectively with limited toxicity is one of the most important goals of current cancer 
research (Hajitou et al., 2006). Most chemotherapeutic drugs do not preferentially 
accumulate at the disease sites. In fact, the dose that reaches the tumor can be as low as 5 
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to 10% of the dose that accumulates in normal tissues (Bosslet et al., 1998). One 
approach in the development of more selective anticancer agents consists of targeted 
delivery of molecules to the tumor microenvironment by binding molecules specifically 
to tumor-associated markers (Borsi et al., 2002; Buchegger et al., 1983; Demartis et al., 
2001; Mach et al., 1983). Tumor progression requires the formation of new blood vessels 
(Folkman, 1971). Therefore, several angiogenesis inhibitors have been developed to 
target endothelial cells and block tumor growth (Kerbel and Folkman, 2002). Targeting 
cells that support tumor growth, rather than cancer cells themselves, is an attractive 
approach for cancer therapy. The vascular endothelium is directly accessible to drugs 
injected in the circulation, is composed of genetically stable cells, and is less likely to 
accumulate mutations and acquire drug resistance (Kerbel and Folkman, 2002; Kolonin et 
al., 2001; St Croix et al., 2000). Although, recent studies in several experimental models 
suggested that both tumor and non-tumor (stromal) cells may be involved in the reduced 
responsiveness to the treatments, due to acquired resistance to antiangiogenic therapy 
(Shojaei and Ferrara, 2008). 
Studies with antiangiogenic agents, including monoclonal antibodies that target 
vascular endothelial growth factor (VEGF) such as bevacizumab, and multitargeted 
receptor tyrosine kinase inhibitors such as sorafenib and sunitinib, have shown to 
improve overall survival in several solid malignancies (Le Tourneau and Siu, 2008). 
Bevacizumab was the first antiangiogenic drug to be approved by the FDA in 2004 
(Hicklin and Ellis, 2005). It is currently used for treatment of metastatic colorectal 
cancer, non-small lung cancer, and advanced breast cancer (Kerbel, 2008). Sorafenib and 
sunitinib have also been approved by the FDA, and are used for the treatment of 
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metastatic renal cell cancer and hepatocellular carcinoma (Kerbel, 2008). The fact that 
HNSCC express high levels of VEGF and its receptors, and that VEGF expression is 
highly correlated with prognosis in patients with HNSCC (Shang et al., 2006; (Lothaire et 
al., 2006), make the study of antiangiogenic therapies especially attractive in the context 
of this malignancy. Although single-agent antiangiogenic drugs have not shown activity 
in HNSCC patients, promising results have been obtained with combination therapies 
involving antiangiogenic drugs in phase II trials (Fujita et al., 2007; Liang et al., 2008). 
 Despite all the advances in therapies targeting VEGF and other signaling 
molecules, several challenges still remain. The survival benefits of these treatments are 
relatively modest (Kerbel, 2008), the treatments are costly (Berenson, 2006; Schrag, 
2004), and have significant side effects (Eskens and Verweij, 2006; Verheul and Pinedo, 
2007). In addition, single-agent therapy that is effective initially may ultimately lead to 
drug resistance (Dietz et al., 2008; Le Tourneau and Siu, 2008), making the development 
of targeted therapies in HNSCC more challenging. The finding of novel molecular 
targets, and the inclusion of these agents in combined treatment regimes, is likely to 
increase therapeutic efficacy in HNSCC. 
 
Materials and Methods 
 
Cell culture 
Oral squamous cell carcinoma (OSCC3, gift of M. Lingen, University of 
Chicago), were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 
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and 100 μg/ml streptomycin (Invitrogen). Tumor cells were serum-starved overnight 
before adding treatment. An immortalized human oral keratinocyte cell line (HOK-16B, 
gift of No-Hee Park, University of California, Los Angeles) was cultured in serum free 
medium OKM (ScienCell, Carlsbad, CA) containing 1% penicillin/streptomycin, and 
supplemented with 5 µg/ml BSA, 5 µg/ml transferring, 50 µg/ml bovine pituitary extract, 
2.5 µg/ml insulin, 1 ng/ml FGF, 500 ng/ml epinephrine, 1 µg/ml hydrocortisone, 30 nM 
prostaglandin, and 40 µg/ml plant extract (OKGS, BulletKit, ScienCell). Cells were 
incubated overnight with OKM medium without supplements before adding treatment. 
Primary human dermal microvascular endothelial cells (HDMEC; Cambrex, 
Walkersville, MD) were cultured in endothelial growth medium-2 (EGM2-MV; 
Cambrex). Conditioned medium (CM) from HDMEC or OSCC3 were prepared in 
endothelial cell medium (EBM) without supplementation with growth factors or serum 
from 24-hour cultures. 
 
Stable short hairpin RNA (shRNA) transduction 
Lentiviruses expressing a short hairpin RNA (shRNA) construct for silencing IL-6 
(Vector Core, University of Michigan) were generated in human embryonic kidney cells 
(293T) transfected by the calcium phosphate method, as described (Kaneko et al., 2007). 
A scrambled oligonucleotide sequence (shRNA-C) was used as control. Supernatants 
were collected 48 hours after transfection and used to infect HDMEC in 1:1 dilution 
medium containing 4 µg/ml polybrene (Sigma-Aldrich, St. Louis, MO). Cells were 
selected in EGM2-MV supplemented with 1 µg/ml puromycin (InvivoGen, San Diego, 
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CA). Downregulation of IL-6 was confirmed by ELISA and by expression of GFP under 
fluorescence microscopy.  
 
Western blots 
8 x 105 OSCC3 were plated in 60 mm dishes, starved overnight, and exposed to 
EBM, or conditioned medium (CM) collected from HDMEC or OSCC3 for the indicated 
time points. HDMEC CM and OSCC3 CM were normalized by total protein 
concentration. In addition, HOK-16B were exposed to HDMEC CM. Alternatively, 
tumor cells were exposed to rhIL-6 (BDP, NCI, Frederick, MD) for the indicated time 
points. Signaling pathways were blocked by pre-incubating tumor cells for 1-2 hours with 
20 µM Stattic (STAT3 inhibitor V, Calbiochem, San Diego, CA), 20 µM LY294002 (PI3 
kinase inhibitor, Cell Signaling Technology, Danvers, MA), or 20 µM U0126 (MEK1/2 
inhibitor, Cell Signaling), as described (Neiva et al., 2009), and exposed to HDMEC CM 
or rhIL-6 for the indicated time points. Protein (30 µg) was electrophoresed on SDS-
polyacrylamide gels and transferred to nitrocellulose membranes. Primary antibodies 
were: mouse anti-human phospho-STAT3, rabbit anti-human STAT3, rabbit anti-human 
phospho-Akt, rabbit anti-human Akt, rabbit anti-human phospho-ERK1/2, mouse anti-
human ERK1/2 (Cell Signaling); and mouse anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; Chemicon, Millipore, Billerca, MA). Immunoreactive proteins 
were visualized by SuperSignal West Pico chemiluminescent substrate (Thermo 
Scientific, Rockford, IL). 
 
Enzyme-linked immunosorbent assay (ELISA) 
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Supernatants of 24-hour endothelial or tumor cell cultures were collected and 
centrifuged to eliminate debris. IL-6 expression was determined using ELISA kits 
(Quantikine; R & D Systems, Minneapolis, MN) according to the manufacturer’s 
instructions. Data were normalized by cell number. 
 
Severe Combined Immunodeficient (SCID) Mouse Model of Human Tumor 
Angiogenesis  
Xenograft human tumors vascularized with human blood vessels were generated 
under an UCUCA approved protocol, as described (Nor et al., 2001a; Nor et al., 2001b). 
Briefly, highly porous poly-L(lactic) acid (Boehringer Ingelheim, Ingelheim, Germany) 
scaffolds were seeded with 9 x 105 HDMEC and 1 x 105 OSCC3 in a 1:1 mixture of 
growth factor reduced Matrigel and EGM2-MV. Alternatively, tumors were generated 
using a line of human Kaposi’s sarcoma cells (SLK, gift of G. Nuñez, University of 
Michigan). In addition, scaffolds were seeded with 9 x 105 HDMEC-shRNA-control or 
HDMEC-shRNA-IL-6 and 1 x 105 OSCC3. SCID mice (5-7-week-old male CB.17.SCID; 
Charles River Laboratories International, Inc., Wilmington, MA) were anesthetized with 
ketamine and xylazine, and 2 scaffolds were implanted in the subcutaneous space of the 
dorsal region of each mouse. Tumors were measured with a caliper every 2 days, starting 
at 14 days after implantation. Mice were euthanized after 28 days, implants were 
retrieved, photographed, measured, weighed on an electronic balance, fixed overnight in 




Immunohistochemistry of tissue sections 
 Immunohistochemistry was performed in paraffin-embedded serial sections using 
phospho-STAT3 (Santa Cruz), STAT3, phospho-Akt, Akt, phospho-ERK, ERK (Cell 
Signaling), and Ki-67 (Biocare Medical, Concord, CA) antibodies, as described (Squarize 
et al., 2006). 
 
Tumor microvessel density 
Tumor microvessel density was determined following identification of blood 
vessels by immunohistochemistry with a polyclonal anti-human factor VIII antibody (Lab 
Vision, Fremont, CA), as previously described (Nor et al., 2001b). The number of stained 
microvessels was counted in 10 random fields per implant in a light microscope at 100X. 
Twelve implants were analyzed per condition.  
 
Statistical analyses  
T-tests or one-way analysis of variance was performed using the SigmaStat 2.0 




Endothelial cell-secreted factors, but not tumor cell-secreted factors, induce 
phosphorylation of STAT3, Akt, and ERK signaling pathways in oral squamous cell 
carcinoma cells 
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 We have previously demonstrated that a crosstalk initiated by endothelial cells 
enhances tumor cell survival and migration in vitro via STAT3, Akt, and ERK signaling 
(Neiva et al., 2009). The overall hypothesis underlying this study is that the activation of 
signaling pathways in tumor cells induced by endothelial cell-secreted factors enhances 
tumor growth. To begin to address this hypothesis, we compared the effect of endothelial 
cell-secreted factors (paracrine pathway) with tumor cell-secreted factors (autocrine 
pathway) on the phosphorylation of STAT3, Akt, and ERK in HNSCC cells. We exposed 
OSCC3 to serum-free endothelial cell (HDMEC) conditioned medium (CM) or tumor 
cell (OSCC3) CM and analyzed phosphorylation events over time (Figure 3.1A). We 
observed that phosphorylation levels of STAT3, Akt, and ERK were higher in tumor cells 
exposed to endothelial cell CM than in tumor cells exposed to OSCC3 CM, or 
unconditioned medium (EBM). The induction of phosphorylation was observed primarily 
at early time points (15 to 30 minutes), decreasing at 1 hour (Figure 3.1A). 
 
Endothelial cell-secreted factors activate STAT3, Akt, and ERK in oral squamous 
cell carcinoma cells and in oral keratinocytes 
 Trying to understand whether the effect of endothelial cell-secreted factors was 
specific to tumor cells (OSCC3), we also exposed human oral keratinocytes (HOK-16B) 
to endothelial cell CM and analyzed phosphorylation of STAT3, Akt, and ERK over time 
(Figure 3.1B). We observed that endothelial cell-secreted factors had a similar effect on 
STAT3 and ERK phosphorylation in keratinocytes, compared to tumor cells (higher 
phosphorylation levels at 15 to 30 minutes, and decreasing at 1 to 24 hours). STAT3 
phosphorylation levels were very similar in both cell lines, whereas phosphorylation of 
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ERK was stronger in tumor cells compared with keratinocytes. Phosphorylation of Akt 
followed a different trend. Similarly to STAT3 and ERK activation, tumor cells 
phosphorylated Akt only in the presence of endothelial cell CM (15 minutes to 1 hour, 
decreasing at 24 hours). On the other hand, oral keratinocytes presented comparable Akt 
phosphorylation levels in the untreated (exposed to EBM unconditioned medium) and 
treated (exposed to endothelial cell CM) groups (Figure 3.1B).  
 
Oral squamous cell carcinoma cells adjacent to blood vessels show increased 
phosphorylation of STAT3, Akt, and ERK in vivo. 
 To evaluate whether the trends of endothelial cell-induced phosphorylation of 
STAT3, Akt, and ERK in tumor cells in vitro translate into increased phosphorylation 
levels in vivo, we used the SCID mouse model of human tumor angiogenesis in which we 
engineer human tumors vascularized with human functional blood vessels that 
anastomize with the mouse vasculature (Nor et al., 2001a; Nor et al., 2001b; Warner et 
al., 2008). We implanted primary human endothelial cells (HDMEC) together with oral 
squamous cells carcinoma cells (OSCC3) in the subcutaneous of SCID mice and analyze 
the tissues by immunohistochemistry. We observed that levels of total STAT3, Akt, and 
ERK were uniform through the tissues with nuclear and cytoplasmic localization (Figure 
3.1C, bottom panels). Interestingly, tumor cells adjacent to blood vessels showed 
phosphorylation of STAT3, Akt, and ERK, with nuclear localization (Figure 3.1C, top 
and middle panels). To validate these results, we coimplanted endothelial cells with a 




STAT3 phosphorylation induced by endothelial cell-secreted factors is independent 
of Akt and ERK phosphorylation in oral squamous cell carcinoma cells 
 To explore the interdependence of molecular signaling events initiated by 
endothelial cells on tumor cells, we exposed OSCC3 to HDMEC CM in the presence of 
chemical inhibitors of STAT3, Akt, or ERK pathways and analyzed the interdependency 
of the phosphorylation events. To establish a baseline, we exposed OSCC3 to HDMEC 
CM and analyzed phosphorylation of STAT3, Akt, and ERK with a detailed time course 
up to 1 hour (Figure 3.3A). We observed that HDMEC CM induces first ERK 
phosphorylation (with strong activation as early as 1 minute, persisting until 15 minutes, 
and decreasing at 30 minutes), followed by STAT3 and Akt (increasing until 15 minutes, 
and maintaining activation for up to 1 hour) (Figure 3.3A). When we decreased STAT3 
phosphorylation using the chemical inhibitor Stattic, we did not observe significant 
changes in the phosphorylation status of Akt or ERK (Figure 3.3B). However, when we 
inhibited Akt phosphorylation using the PI3K inhibitor LY294002 we observed an 
increase in ERK phosphorylation levels (maintaining strong phosphorylation for up to 1 
hour), while phosphorylation levels of STAT3 did not change (Figure 3.3C). Similarly, 
when we inhibited ERK phosphorylation using the MEK1/2 inhibitor U0126 we observed 
increased Akt phosphorylation (maintaining strong phosphorylation for up to 1 hour), 
whereas phosphorylation levels of STAT3 remained unchanged (Figure 3.3D). 
 We then extended our time course experiments for 24 hours, and observed the 
same relationship between STAT3, Akt, and ERK phosphorylation in tumor cells induced 
by endothelial cell-secreted factors (Figure 3.4). STAT3, Akt, and ERK phosphorylation 
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were stronger at early time points (15 to 30 minutes), decreasing over time. 
Phosphorylation levels of STAT3 decreased at 1 hour and were maintained for up to 24 
hours, phosphorylation of Akt decreased at 2 hours and disappeared at 4 to 24 hours, 
while phosphorylation of ERK decreased significantly at 1 hour and was absent at 3 to 24 
hours (Figure 3.4A). Following the same trends as Figure 3.3, inhibition of STAT3 
phosphorylation did not affect Akt or ERK phosphorylation levels (Figure 3.4B). On the 
other hand, inhibition of Akt phosphorylation increased activation of ERK (Figure 3.4C) 
at 1 to 24 hours (compared with Figure 3.4A). Likewise, inhibition of ERK 
phosphorylation increased Akt activation (Figure 3.4D), maintaining the phosphorylation 
state longer (compared with Figure 3.4A). No major effect was observed in STAT3 
phosphorylation levels using Akt or ERK inhibitors. These results suggested that 
endothelial cell-induced Akt and ERK phosphorylation in OSCC3 have a compensatory 
effect, while the STAT3 pathway is activated independently. 
 
IL-6 activates STAT3, Akt, and ERK signaling pathways in oral squamous cell 
carcinoma cells 
We have previously demonstrated that IL-6, CXCL8, and EGF are involved in the 
endothelial cell-initiated STAT3, Akt, and ERK signaling in HNSCC cells, respectively. 
From these three endothelial cell-secreted factors, IL-6 was the cytokine that activated 
pathways in HNSCC more significantly, particularly STAT3 (Neiva et al., 2009). To 
understand HNSCC response to IL-6 stimulation, we performed a detailed time course 
analyzing the phosphorylation events in OSCC3 cells (Figure 3.5). We observed that 
when tumor cells were exposed to rhIL-6, the phosphorylation of STAT3, Akt, and ERK 
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followed similar patterns as when tumor cells were exposed to HDMEC CM (Figures 
3.4A and 3.5A). We then exposed tumor cells to IL-6 in the presence of chemical 
inhibitors of STAT3, Akt, or ERK pathways and analyzed the phosphorylation response 
(Figures 3.5B-E). IL-6 strongly activated STAT3 pathway in OSCC3, and slightly 
activated Akt or ERK (Figure 3.5B). Blockade of STAT3 phosphorylation had no major 
effect on Akt, but increased ERK phosphorylation (Figure 3.5C). Blockade of Akt 
activation had no effect on STAT3, while increased ERK phosphorylation (Figure 3.5D). 
Lastly, inhibition of ERK phosphorylation had significant effect on STAT3 or Akt 
phosphorylation (Figure 3.5E). Collectively, these results demonstrated that the major 
effect of IL-6 in OSCC3 is the activation of the STAT3 pathway. 
 
STAT3 phosphorylation in xenograft human oral squamous cell carcinomas 
correlates with tumor cell proliferation and presence of blood vessels 
Our mechanistic experiments in which we inhibited endothelial cell- or IL-6-
induced STAT3, Akt, or ERK pathways in tumor cells, suggested that STAT3 is activated 
independently of Akt and ERK activation. Furthermore, IL-6 activates mainly STAT3 
signaling, while less robust effect on the phosphorylation of Akt and ERK was observed 
in OSCC3. These results led us to further explore the IL-6/STAT3 signaling in vivo. We 
used the SCID mouse model of human tumor angiogenesis, in which we implanted highly 
porous biodegradable scaffolds cointaining OSCC3 and endothelial cells, generating 
xenograft human oral squamous cell carcinomas. After 28 days, tumors were retrieved 
and tissues were analyzed by immunohistochemistry. Confirming our previous results 
(Figure 3.1C), we observed that while total STAT3 was present diffuse through the entire 
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tissue (Figure 3.6A) phosphorylated STAT3 had a tendency to concentrate adjacent blood 
vessels (Figure 3.6B). Interestingly, immunostaining for the cell proliferation marker 
Ki67 showed the same pattern as phosphorylated STAT3 (Figure 3.6C). These results 
suggested that phosphorylation of STAT3 in oral squamous cell carcinomas correlates 
with tumor cell proliferation and proximity to blood vessels.  
 
Downregulation of IL-6 in tumor-associated endothelial cells inhibits tumor growth 
 We have previously demonstrated that downregulation of IL-6 in endothelial cells 
decreases tumor cell survival and migration in vitro (Neiva et al., 2009). These results led 
us to investigate the role of endothelial cell-secreted IL-6 on HNSCC. To investigate 
whether these in vitro trends have a biological effect in vivo, we used the SCID mouse 
model of human tumor angiogenesis and seeded OSCC3 together with endothelial cells 
secreting low levels of IL-6 (HDMEC-shRNA-IL-6), or endothelial cells secreting high 
levels of IL-6 (HDMEC-shRNA-control). Initially, we downregulated IL-6 expression in 
endothelial cells using lentivirus. The effectiveness of the knockdown was verified by 
ELISA (Figure 3.7A), and under fluorescence microscopy to confirm expression of GFP-
positive cells (Figure 3.7B). We then implanted scaffolds seeded with OSCC3 and 
HDMEC-shRNA-IL-6 or HDMEC-shRNA-control in the subcutaneous of SCID mice, 
and observed tumor growth overtime. We observed a significant difference in tumor 
growth between the two groups. Tumors populated with HDMEC-shRNA-control grew 
faster and reached 2,000 mm3 at 28 days after implantation, whereas tumors populated 
with endothelial cells secreting low levels of IL-6 presented approximately half of this 
size (Figure 3.7C). Tumors were macroscopically smaller in the group populated with 
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HDMEC-shRNA-IL-6 compared with the control group (Figure 3.7D, a). Mice were 
euthanized at 28 days post-implantation, tumors were removed, photographed (Figure 
3.7D, b), measured (Figure 3.7E, a), and weighted (Figure 3.7E, b). These results 
demonstrated that downregulation of IL-6 in tumor-associated endothelial cells is 
sufficient to inhibit tumor growth. 
 
Downregulation of IL-6 in tumor-associated endothelial cells inhibits tumor cell 
proliferation and decreases intratumoral microvessel density. 
 To explore the mechanisms involved in the inhibition of tumor growth mediated 
by downregulation of IL-6 in endothelial cells, we analyzed by immunohistochemistry 
tumor cell proliferation and intratumoral microvessel density. We observed that 
expression of the proliferation marker Ki67 was higher in tumors cells coimplanted with 
HDMEC-shRNA-control than in tumors cells coimplanted with HDMEC-shRNA-IL-6 
(Figure 3.8A). Ki67 expression was quantified by blinded scoring the immunostained 
tissues (Figure 3.8B). Lastly, we analyzed whether downregulation of IL-6 in tumor-
associated endothelial cells affect microvessel density. We observed a significant 
decrease in microvessel density in tumors populated with OSCC3 and HDMEC-shRNA-
IL-6, compared to implants containing OSCC3 and HDMEC-shRNA-control (Figure 
3.8C). Number of microvessels was quantified by counting vessels stained for von 
Willebrand factor (Factor VIII) (Figure 3.8D). Taken together, these results demonstrated 
that downregulation of IL-6 in tumor-associated endothelial cells reduces tumor cell 





Recently, there has been increasing interest in the development of molecular-
targeted agents that specifically modulate growth factors and signaling pathways that are 
deregulated in tumor cells. A better understanding of the molecular mechanisms 
underlying the development and progression of HNSCC may help to identify novel 
targets for pharmacological intervention in this devastating disease (Nagpal and Das, 
2003; Squarize et al., 2006).  
We have previously shown that factors secreted by endothelial cells, namely IL-6, 
CXCL8, and EGF, activate STAT3, Akt, or ERK signaling pathways in HNSCC, 
increasing tumor cell survival and migration in vitro (Neiva et al., 2009). In this study, 
we explore the biological consequences of these endothelial cell-initiated signaling events 
in vivo. In our previous report, we demonstrated that conditioned medium collected from 
endothelial cells stimulate phosphorylation of STAT3, Akt, and ERK in HNSCC. 
However, we did not know whether activation of these pathways was specific to 
endothelial cell-secreted factors. Several studies describe an autocrine effect of tumor 
cell-secreted factors on cancer progression (Gao et al., 2007; Kulbe et al., 2004; Lee et 
al., 2007a; Molinolo et al., 2009; Pries and Wollenberg, 2006; Sansone et al., 2007). 
Here, we demonstrated that tumor cells exposed to endothelial cell conditioned medium 
had higher levels of STAT3, Akt, and ERK phosphorylation that tumor cells exposed to 
conditioned medium collected from tumor cells. We recognize that tumor cells secrete a 
panel of growth factors and cytokines that stimulate a network signaling molecules. 
However, endothelial cells activated STAT3, Akt, and ERK in a significantly greater 
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extend than tumor cell-secreted factors in an autocrine manner. These results support our 
previous findings that endothelial cells secrete significantly higher levels of IL-6, 
CXCL8, and EGF than HNSCC cells (Neiva et al., 2009). We also explored whether 
these endothelial cell-initiated phosphorylation events were specific to advanced stage 
carcinoma cell lines. To address this question, we exposed a human oral keratinocyte cell 
line to endothelial cell conditioned medium and analyzed phosphorylation of STAT3, Akt 
and ERK. We observed that endothelial cells were also able to activate STAT3 and ERK 
pathways in keratinocytes, suggesting that factors secreted by endothelial cells may also 
play a role in the early events of HNSCC tumorigenesis. The fact that keratinocytes 
responded similarly to tumor cells, and more importantly, that Akt was phosphorylated 
even in untreated cells might be explained by the model of molecular cancer progression 
of HNSCC (Califano et al., 1996b). This model postulated that tissues with normal or 
benign appearance might already contain clonal genetic changes (Forastiere et al., 2001). 
In addition, several studies suggest that early genetic changes do not necessarily correlate 
with observable changes in morphology (Rosin et al., 2000). 
 To move our study forward, it was important for us to verify whether these in 
vitro findings would have a correlation with in vivo levels of STAT3, Akt, and ERK 
phosphorylation in tumor cells associated with the presence of endothelial cells. Using 
the SCID mouse model of human tumor angiogenesis (Nor et al., 2001a; Nor et al., 
2001b; Warner et al., 2008), we co-implanted primary human endothelial cells with 
human oral squamous cells carcinoma cells and analyzed phosphorylation of STAT3, 
Akt, and ERK in the tumor tissues by immunohistochemistry. Notably, the levels of total 
STAT3, Akt, and ERK were uniformly distributed through the tumor mass, while tumor 
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cells expressing phosphorylated STAT3, Akt, and ERK were localized adjacent to blood 
vessels. We validated these results using a tumor cells line from mesenquimal origin 
(Kaposi’s sarcoma), showing that the effect of endothelial cells on tumor cell 
phosphorylation of STAT3, Akt, and ERK was independent of tumor type. 
  Several studies have shown that deregulation of STAT3, Akt, and ERK is 
implicated in tumorigenesis (Chang et al., 2003; Friday and Adjei, 2008; Grandis et al., 
1998; Leeman et al., 2006; Luo et al., 2003; Roberts and Der, 2007; Song and Grandis, 
2000; Squarize et al., 2006; Vivanco and Sawyers, 2002; Zeng et al., 2002), suggesting 
that aberrant activity of a network of interrelated signaling pathways rather than a single 
deregulated route contributes to carcinogenesis (Molinolo et al., 2009). We have shown 
that endothelial cell-secreted factors activate STAT3, Akt, and ERK signaling in HNSCC 
(Neiva et al., 2009), however the crosstalk between these three pathways initiated by 
endothelial cells had not been explored. Trying to understand the relationship between 
these endothelial cell-initiated signaling events on tumor cells, we exposed OSCC3 to 
endothelial cell conditioned medium in the presence of chemical inhibitors of STAT3, 
Akt, and ERK pathways and analyzed the phosphorylation response. When we inhibited 
STAT3 phosphorylation, we observed no major changes in the activation of Akt or ERK. 
However, when we inhibited Akt phosphorylation, we observed an increase in ERK 
phosphorylation and vice-versa, whereas inhibition of Akt or ERK did not affect STAT3 
phosphorylation levels. These results suggested that endothelial cell-induced Akt and 
ERK signaling have a compensatory effect, while STAT3 pathway is activated 
independently. These results are in accordance with accumulating evidence that Akt and 
ERK pathways may cooperate to promote the survival of transformed cells, and are 
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alternatively and/or coordinately expressed in several cancers, raising the possibility that 
a feedback loop might exist in this network (Carracedo et al., 2008; Gao et al., 2006; 
Grant, 2008; Kinkade et al., 2008; McCubrey et al., 2007; Uzgare and Isaacs, 2004). Our 
results showed that IL-6 secreted by endothelial cells strongly activated STAT3 in 
OSCC3. Several other studies have also demonstrated that IL-6 induces STAT3 in other 
cell types and diseases (Atreya and Neurath, 2008; Hirano et al., 2000; Hodge et al., 
2005; Van Snick, 1990).  
Next, we explored the role of endothelial cell-secreted IL-6 on tumor growth, 
using the SCID mouse model or human tumor angiogenesis. We observed a significant 
difference in tumor growth over time, tumor volume, and tumor weight when tumor-
associated endothelial cells expressed low levels of IL-6. Early studies have shown that 
upregulation of Bcl-2 in microvascular endothelial cells accelerates tumor growth 
(Kaneko et al., 2007; Nor et al., 2001a). We have previously demonstrated that 
endothelial cells overexpressing Bcl-2 secrete higher levels of IL-6 than empty vector 
control cells (Neiva et al., 2009). These two findings support the results we presented 
here. We then explored the mechanisms involved in the inhibition of tumor growth by 
immunohistochemistry. Consistently with our previous results, tumor cells expressing 
phosphorylated STAT3 were located primarily adjacent to blood vessels and correlated 
with expression of the proliferation marker Ki67. Notably, expression of Ki67 was higher 
in tumors populated with OSCC3 and HDMEC-shRNA-control than in tumors populated 
with endothelial cells secreting low levels of IL-6. Lastly, we observed a significant 
decrease in microvessel density in tumors populated with OSCC3 and HDMEC-shRNA-
IL-6, compared to controls. Collectively, these results demonstrated that downregulation 
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of IL-6 in tumor-associated endothelial cells reduces tumor cell proliferation and 
decreases microvessel density, leading to an inhibition of tumor growth. Our results are 
in accordance with several reports describing that STAT3 plays a crucial role in tumor 
cell proliferation and angiogenesis, and that IL-6 is the major activator of STAT3 
pathway (Aggarwal et al., 2006; Hodge et al., 2005; Leeman et al., 2006). 
In this study, we demonstrated that specific inhibition of endothelial cell-secreted 
IL-6 inhibits tumor growth. Targeting the vascular endothelium rather than the cancer 
cells has been an attractive therapeutic approach for the treatment of several malignancies 
(Kerbel and Folkman, 2002). Notably, endothelial cells are directly accessible to systemic 
drugs, are composed of genetically stable cells, and are less likely to accumulate 
mutations and acquire drug resistance (Kerbel and Folkman, 2002; Kolonin et al., 2001; 
St Croix et al., 2000). In addition, our results suggest that therapeutic blockade of 
signaling events initiated by endothelial cells might be beneficial for cancer patients even 




Figure 3.1. Endothelial cell-derived factors phosphorylate STAT3, Akt, and ERK in 
tumor cells in vitro and in vivo. (A) Western blot for phosphorylated and total STAT3, 
Akt, and ERK in OSCC3 serum-starved overnight and exposed to HDMEC conditioned 
medium (CM), OSCC3 CM, or control unconditioned medium (EBM) for the indicated 
time points. (B) Western blot for phosphorylated and total STAT3, Akt, and ERK in 
OSCC3 or HOK-16B serum-starved overnight and exposed to HDMEC CM or EBM for 
the indicated time points. (C) Immunohistochemical analysis for STAT3, Akt, and ERK 
in representative specimens from xenograft human squamous cell carcinomas. Top panels 
represent photomicrographs of phosphorylated STAT3, Akt, and ERK, with nuclear 
localization (100X). Middle panels represent higher magnification (200X). Arrows point 
to blood vessels. Bottom panels represent total STAT3, Akt, and ERK (100X) with 




Figure 3.2. Tumor cells adjacent to blood vessels show increased phosphorylation of 
STAT3, Akt, and ERK. (A) Immunohistochemical analysis for phosphorylated STAT3, 
Akt, and ERK in representative specimens from xenografted human Kaposi’s sarcomas. 
Top panels represent 100X and bottom panels represent 200X. (B) Immunostaining for 





Figure 3.3. Blockade of endothelial cell-induced STAT3 phosphorylation in tumor 
cells does not affect Akt and ERK pathways, whereas inhibition of Akt or ERK have 
a compensatory mechanism and do not affect STAT3. OSCC3 were serum-starved 
overnight and exposed to (A) HDMEC conditioned medium (CM) or unconditioned 
medium (EBM) for the indicated time points. In addition, OSCC3 were pre-incubated for 
1 to 2 hours with (B) 20 µM Stattic, (C) 20 µM LY294002, or (D) 20 µM U0126, and 
then exposed to HDMEC CM or EBM for the indicated time points. Phosphorylated and 




Figure 3.4. STAT3 phosphorylation induced by endothelial cell-secreted factors is 
independent of Akt and ERK phosphorylation. OSCC3 were serum-starved overnight 
and exposed to (A) HDMEC conditioned medium (CM) or unconditioned medium 
(EBM) for the indicated time points. In addition, OSCC3 were pre-incubated for 1 to 2 
hours with (B) 20 µM Stattic, (C) 20 µM LY294002, or (D) 20 µM U0126, and then 
exposed to HDMEC CM or EBM for the indicated time points. Phosphorylated and total 
levels of STAT3, Akt, and ERK were determined by Western blot. 
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Figure 3.5. IL-6 potently activates STAT3 signaling in oral squamous cell carcinoma 
cells. (A-E) OSCC3 were serum-starved overnight and exposed to 20 ng/ml rhIL-6 for 
the indicated time points. Phosphorylated and total levels of STAT3, Akt, and ERK were 
determined by Western blots. (A) Extensive and detailed time course in OSCC3 exposed 
to rhIL-6. (B) Short time course in OSCC3 exposed to rhIL-6. In addition, OSCC3 were 
pre-incubated for 1 to 2 hours with (C) 20 µM Stattic, (D) 20 µM LY294002, or (E) 20 





Figure 3.6. STAT3 phosphorylation in xenograft human oral squamous cell 
carcinomas correlates with tumor cell proliferation and presence of blood vessels. 
Xenograft human tumors were generated in SCID mice by coimplanting OSCC3 and 
HDMEC. Tumors were retrieved after 28 days, and tissues were analyzed by 
immunohistochemistry. Immunohistochemical analysis for (A) total STAT3 with nuclear 
and cytoplasmic localization, diffused through the tissue. (B) phosphorylated STAT3 
with nuclear localization, concentrated in the proximity of blood vessels. (C) Ki67 with 
nuclear localization, concentrated adjacent to blood vessels. Top panels represent 100X 




Figure 3.7. Downregulation of IL-6 in tumor-associated endothelial cells inhibits 
tumor growth. (A) ELISA for IL-6 expression in HDMEC transfected with shRNA-IL-6 
or with a control scrambled oligonucleotide sequence (shRNA-C). (B) Fluorescence 
microscopy showing GFP expression in transfected-positive cells. (C) Tumor progression 
over time. (D) Macroscopic view of representative SCID mice bearing tumors (a), and 
the same tumors after retrieval (b). (E) Graphs depicting tumor volume (a) and tumor 






Figure 3.8. Downregulation of IL-6 in tumor-associated endothelial cells reduces 
tumor cell proliferation and decreases intratumoral microvessel density. (A) 
Immunohistochemical analysis for Ki67, indicating tumor cell proliferation in implants 
containing OSCC3 and HDMEC-shRNA-C, or OSCC3 and HDMEC-shRNA-IL-6 (top 
panels represent 100X and bottom panels represent 200X). (B) Quantification of tumor 
cell proliferation determined by scoring Ki67 immunostaining. Data represent mean 
values obtained in random microscopic fields (100X) from 12 tumors per condition. 
Asterisk depicts significant difference (p<0.05). (C) Immunohistochemistry for von 
Willebrand factor (Factor VIII) showing blood vessels (100X). Left panel shows a 
representative tumor populated with OSCC3 and HDMEC-shRNA-C, and right panel 
shows a tumor containing OSCC3 and HDMEC-shRNA-IL-6. (D) Quantification of 
microvessel density. Data represent mean values obtained in 10 random microscopic 
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Our understanding of the process involving HNSCC development and progression 
has increased significantly over the past years. However, despite many advances in 
prevention and treatment of HNSCC, several challenges still remain. The poor prognosis 
for patients diagnosed with this devastating disease is in part a consequence of the limited 
knowledge of the signaling events underlying the malignant progression of HNSCC. 
Molecular targeted therapy is a promising approach to treat HNSCC and it has been 
shown to improve overall patient survival (Harari et al., 2009). With that in mind, we 
attempted to gain insights into the complex molecular events involving HNSCC cells and 
endothelial cells. The rationale to explore the crosstalk between endothelial cells and 
cancer cells is based on the knowledge that tumors are angiogenesis-dependent, and that 
this process of tumor angiogenesis requires active interaction between endothelial and 
tumor cells. The current paradigm in this field is that tumor cell-initiated signals are the 
dominant events in tumor angiogenesis and tumor growth, and little is known about the 
effect of endothelial cell-secreted factors on the phenotype and behavior of tumor cells. 
Here, we hypothesized that endothelial cells initiate signaling pathways in HNSCC cells 
that enhance tumor growth. The identification and characterization of the signaling events 
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initiated by tumor-associated endothelial cells may have important implications in cancer 
therapy.  
In chapter II, we demonstrated that soluble mediators from primary human dermal 
microvascular endothelial cells activate three key intracellular molecules, namely 
STAT3, Akt, and ERK in a panel of HNSCC, suggesting that endothelial cells play an 
active role in the determination of tumor cell phenotype. Notably, we showed that 
endothelial cell-secreted factors were able to phosphorylate these signaling pathways in 
tumor cells without cell contact. One of the challenges was to find out which factors were 
mediating these effects in HNSCC cells. We then demonstrated that IL-6, CXCL8, and 
EGF were upregulated in endothelial cells co-cultured with HNSCC, and that blockade of 
endothelial cell-derived IL-6, CXCL8, or EGF inhibited the activation of STAT3, Akt, 
and ERK in tumor cells, respectively.  
Trying to understand the mechanisms involved in this upregulation of IL-6, 
CXCL8, and EGF in endothelial cells, we explored a potential role for Bcl-2, based on 
previous reports. Previous studies have shown that tumor cell-secreted VEGF induces 
Bcl-2 expression in endothelial cells, and that upregulation of Bcl-2 in microvascular 
endothelial cells is sufficient to enhance tumor progression (Nor et al., 1999; Nor et al., 
2001a). Notably, Bcl-2 is significantly upregulated in the endothelial cells of head and 
neck tumor microvessels in human patients (Kaneko et al., 2007). In addition, Bcl-2 
induces CXCL1 and CXCL8 expression in endothelial cells (Karl et al., 2005). We 
observed that Bcl-2 signaling also induces expression of IL-6, CXCL8, and EGF, 
providing a mechanism for the upregulation of these cytokines in tumor-associated 
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endothelial cells. Moreover, Bcl-2 expression in endothelial cells had a significant impact 
on the phosphorylation status of STAT3 and ERK in HNSCC cells. 
At this point, it was critical to us to expand our studies to better understand the 
biological significance of endothelial cell-induced activation of the STAT3, Akt, and 
ERK pathways in HNSCC. We demonstrated that endothelial cell-secreted factors 
significantly protected HNSCC cells from anoikis, and this protective effect was partially 
inhibited when we downregulated IL-6, CXCL8, or EGF in the endothelial cells. And 
finally, considering that IL-6, CXCL8, and EGF have been characterized as chemotactic 
factors, we explored their effect on tumor cell motility. Indeed, we observed that 
endothelial cells were able to generate a chemotactic gradient that induces tumor cell 
migration towards the endothelial cells. Based on these results, we speculated that 
endothelial cells play a key role in field cancerization by providing chemotactic signals 
that enhance the invasive phenotype of tumor cells, and by activating survival signals that 
protect the tumor cells against anoikis once these cells are displaced from their original 
microenvironment.  
In chapter III, we explored the crosstalk between the endothelial cell-induced 
signaling pathways in HNSCC, with an emphasis on IL-6-mediated events. Here, we 
demonstrated that HNSCC cells exposed to endothelial cell conditioned medium 
presented higher levels of STAT3, Akt, and ERK phosphorylation than HNSCC cells 
exposed to conditioned medium collected from tumor cells. Furthermore, we observed 
that endothelial cell-secreted factors were also able to induce STAT3 and ERK 
phosphorylation in oral keratinocytes, suggesting that microvascular endothelial cells 
may also play a role in the early events of HNSCC tumorigenesis.  
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 At this stage, it was important to verify whether these in vitro findings would 
have a correlation with in vivo levels of STAT3, Akt, and ERK phosphorylation in tumor 
cells associated with the presence of endothelial cells. Using the SCID mouse model of 
human tumor angiogenesis (Nor et al., 2001a; Nor et al., 2001b; Warner et al., 2008), we 
demonstrated that tumor cells adjacent to blood vessels express high levels of 
phosphorylates STAT3, Akt, and ERK, whereas total protein was expressed through the 
entire tissues.  
 Several studies suggest that aberrant activity of a network of interrelated 
signaling pathways rather than a single deregulated route contributes to carcinogenesis. 
Therefore, we explore the crosstalk between STAT3, Akt, and ERK signaling initiated by 
endothelial cells. Using chemical inhibitors for these pathways, we observed that 
endothelial cell-induced Akt and ERK signaling have a compensatory effect, while 
STAT3 pathway is activated independently. These results suggested that Akt and ERK 
cooperate in the progression of HNSCC, and that a possible feedback loop might exist in 
this network. On the other hand, STAT3 activation was independent of Akt and ERK 
phosphorylation status. 
Due to the fact that STAT3 was an independent, consistent, and potent pathway 
activated by endothelial cells in HNSCC, we decided to further explore the effect of 
endothelial cell-secreted IL-6 in vivo. Using the SCID mouse model or human tumor 
angiogenesis, we observed a significant inhibition of tumor growth over time, tumor 
volume, and tumor weight when tumor-associated endothelial cells expressed low levels 
of IL-6. In addition, downregulation of IL-6 in tumor-associated endothelial cells reduced 
phosphorylation of STAT3 in tumor cells, inhibited tumor cell proliferation, and 
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decreased intratumoral microvessel density. Targeting the vascular endothelium rather 
than the cancer cells has been an attractive therapeutic approach for the treatment of 
several malignancies, since endothelial cells are directly accessible to systemic drugs, 
genetically stable, and less likely to acquire drug resistance (Kerbel and Folkman, 2002). 
Our results suggest that therapeutic blockade of signaling events initiated by endothelial 
cells might help to optimize the overall therapeutic benefit of molecular targeted drugs. 
The work presented here demonstrated that blockade of specific pathways in tumor 
associated-endothelial cells may have a direct impact on tumor cell survival, migration, 
and overall tumor growth. 
Figure 4.1 proposes a model that incorporates the findings presented in this 
dissertation. We propose this new model for the crosstalk between endothelial and 
HNSCC cells. It is known that tumor cell-secreted VEGF binds to its cognate receptors in 
endothelial cells and induce expression of Bcl-2. Here, we demonstrated that Bcl-2 
enhances IL-6, CXCL8, and EGF synthesis and secretion by endothelial cells. These 
endothelial cell-secreted factors activates STAT3, Akt, and ERK signaling pathways in 
tumor cells. The biological outcome of this crosstalk is a significant increase in tumor 





Figure 4.1. Diagram proposing a model for the endothelial cell-initiated crosstalk 
with tumor cells that is described in this dissertation. Endothelial cells secrete IL-6, 
CXCL8, and EGF that bind to their cognate receptors in tumor cells and induce 
phosphorylation of STAT3, Akt, and ERK. These phosphorylation events enhance tumor 
cell survival and migration. A positive feedback loop can be generated by STAT3 
phosphorylation in tumor cells. It is known that STAT3 signal upregulation of VEGF 
expression in HNSCC and that tumor cell-secreted VEGF induces Bcl-2 expression in 
endothelial cells. Here, we showed that Bcl-2 signaling induces IL-6 secretion by 
endothelial cells, which in turn activate STAT3 in cancer cells, promote tumor 
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